105 results on '"Gambacorta M. A. (ORCID:0000-0001-5455-8737)"'
Search Results
2. Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
- Author
-
Rossi, Ernesto, Schinzari, Giovanni, Cellini, Francesco, Balducci, Mario, Pasqualoni, Mariangela, Maiorano, Brigida Anna, Fionda, Bruno, Longo, Silvia, Deodato, Francesco, Di Stefani, Alessandro, Peris, Ketty, Gambacorta, Maria Antonietta, Tortora, Giampaolo, Rossi E., Schinzari G. (ORCID:0000-0001-6105-7252), Cellini F. (ORCID:0000-0002-2145-2300), Balducci M. (ORCID:0000-0003-0398-9726), Pasqualoni M., Maiorano B. A., Fionda B., Longo S., Deodato F. (ORCID:0000-0003-1276-5070), Di Stefani A., Peris K. (ORCID:0000-0002-5237-0463), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Tortora G. (ORCID:0000-0002-1378-4962), Rossi, Ernesto, Schinzari, Giovanni, Cellini, Francesco, Balducci, Mario, Pasqualoni, Mariangela, Maiorano, Brigida Anna, Fionda, Bruno, Longo, Silvia, Deodato, Francesco, Di Stefani, Alessandro, Peris, Ketty, Gambacorta, Maria Antonietta, Tortora, Giampaolo, Rossi E., Schinzari G. (ORCID:0000-0001-6105-7252), Cellini F. (ORCID:0000-0002-2145-2300), Balducci M. (ORCID:0000-0003-0398-9726), Pasqualoni M., Maiorano B. A., Fionda B., Longo S., Deodato F. (ORCID:0000-0003-1276-5070), Di Stefani A., Peris K. (ORCID:0000-0002-5237-0463), Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Tortora G. (ORCID:0000-0002-1378-4962)
- Abstract
The clinical management of metastatic melanoma has been changed by BRAF (BRAFi) and MEK inhibitors (MEKi), which represent a standard treatment for BRAF-mutant melanoma. In oligoprogressive melanoma patients with BRAF mutations, target therapy can be combined with loco-regional radiotherapy (RT). However, the association of BRAF/MEK inhibitors and RT needs to be carefully monitored for potential increased toxicity. Despite the availability of some reports regarding the tolerability of RT + target therapy, data on simultaneous RT and BRAFi/MEKi are limited and mostly focused on the BRAFi vemurafenib. Here, we report a series of metastatic melanoma patients who received fractioned RT regimens for oligoprogressive disease in combination with the BRAFi dabrafenib and the MEKi trametinib, which have continued beyond progression. None of the cases developed relevant adverse events while receiving RT or interrupted dabrafenib and trametinib administration. These cases suggest that a long period of dabrafenib/trametinib interruption during radiotherapy for oligoprogressive disease can be avoided. Prospective trials are warranted to assess the efficacy and safety of the contemporary administration of BRAF/MEK inhibitors and radiotherapy for oligoprogressive disease.
- Published
- 2023
3. MRI-derived radiomics to guide post-operative management of glioblastoma: Implication for personalized radiation treatment volume delineation
- Author
-
Chiesa, Silvia, Russo, Rosellina, Beghella Bartoli, Francesco, Palumbo, I, Sabatino, Giovanni, Cannatà, M C, Gigli, Riccardo, Longo, Silvia, Tran, H E, Boldrini, Luca, Dinapoli, Nicola, Votta, C, Cusumano, Davide, Pignotti, Fabrizio, Lupattelli, M, Camilli, F, Della Pepa, Giuseppe Maria, D'Alessandris, G Q, Olivi, Alessandro, Balducci, Mario, Colosimo, Cesare, Gambacorta, Maria Antonietta, Valentini, Vincenzo, Aristei, Cynthia, Gaudino, Simona, Chiesa, S (ORCID:0000-0003-0168-3459), Russo, R, Beghella Bartoli, F, Sabatino, G (ORCID:0000-0002-4227-0434), Gigli, R, Longo, S, Boldrini, L, Dinapoli, N, Cusumano, D, Pignotti, F, Della Pepa, G M (ORCID:0000-0001-8698-3359), Olivi, A (ORCID:0000-0002-4489-7564), Balducci, M (ORCID:0000-0003-0398-9726), Colosimo, C (ORCID:0000-0003-3800-3648), Gambacorta, M A (ORCID:0000-0001-5455-8737), Valentini, V (ORCID:0000-0003-4637-6487), Aristei, C, Gaudino, S (ORCID:0000-0003-1681-4343), Chiesa, Silvia, Russo, Rosellina, Beghella Bartoli, Francesco, Palumbo, I, Sabatino, Giovanni, Cannatà, M C, Gigli, Riccardo, Longo, Silvia, Tran, H E, Boldrini, Luca, Dinapoli, Nicola, Votta, C, Cusumano, Davide, Pignotti, Fabrizio, Lupattelli, M, Camilli, F, Della Pepa, Giuseppe Maria, D'Alessandris, G Q, Olivi, Alessandro, Balducci, Mario, Colosimo, Cesare, Gambacorta, Maria Antonietta, Valentini, Vincenzo, Aristei, Cynthia, Gaudino, Simona, Chiesa, S (ORCID:0000-0003-0168-3459), Russo, R, Beghella Bartoli, F, Sabatino, G (ORCID:0000-0002-4227-0434), Gigli, R, Longo, S, Boldrini, L, Dinapoli, N, Cusumano, D, Pignotti, F, Della Pepa, G M (ORCID:0000-0001-8698-3359), Olivi, A (ORCID:0000-0002-4489-7564), Balducci, M (ORCID:0000-0003-0398-9726), Colosimo, C (ORCID:0000-0003-3800-3648), Gambacorta, M A (ORCID:0000-0001-5455-8737), Valentini, V (ORCID:0000-0003-4637-6487), Aristei, C, and Gaudino, S (ORCID:0000-0003-1681-4343)
- Abstract
BackgroundThe glioblastoma's bad prognosis is primarily due to intra-tumor heterogeneity, demonstrated from several studies that collected molecular biology, cytogenetic data and more recently radiomic features for a better prognostic stratification. The GLIFA project (GLIoblastoma Feature Analysis) is a multicentric project planned to investigate the role of radiomic analysis in GB management, to verify if radiomic features in the tissue around the resection cavity may guide the radiation target volume delineation. Materials and methodsWe retrospectively analyze from three centers radiomic features extracted from 90 patients with total or near total resection, who completed the standard adjuvant treatment and for whom we had post-operative images available for features extraction. The Manual segmentation was performed on post gadolinium T1w MRI sequence by 2 radiation oncologists and reviewed by a neuroradiologist, both with at least 10 years of experience. The Regions of interest (ROI) considered for the analysis were: the surgical cavity +/- post-surgical residual mass (CTV_cavity); the CTV a margin of 1.5 cm added to CTV_cavity and the volume resulting from subtracting the CTV_cavity from the CTV was defined as CTV_Ring. Radiomic analysis and modeling were conducted in RStudio. Z-score normalization was applied to each radiomic feature. A radiomic model was generated using features extracted from the Ring to perform a binary classification and predict the PFS at 6 months. A 3-fold cross-validation repeated five times was implemented for internal validation of the model. ResultsTwo-hundred and seventy ROIs were contoured. The proposed radiomic model was given by the best fitting logistic regression model, and included the following 3 features: F_cm_merged.contrast, F_cm_merged.info.corr.2, F_rlm_merged.rlnu. A good agreement between model predicted probabilities and observed outcome probabilities was obtained (p-value of 0.49 by Hosmer and Lemeshow statistical te
- Published
- 2023
4. Art and digital technologies to support resilience during the oncological journey: The Art4ART project
- Author
-
Tagliaferri, Luca, Dinapoli, Loredana, Casa, Cristina, Colloca, Giuseppe Ferdinando, Marazzi, Fabio, Cornacchione, Patrizia, Mazzarella, Maria Cristina, Masiello, Valeria, Chiesa, Silvia, Beghella Bartoli, Francesco, Marconi, Elisa, D'Oria, Marika, Cesario, Alfredo, Chieffo, Daniela Pia Rosaria, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Tagliaferri L. (ORCID:0000-0003-2308-0982), Dinapoli L., Casa C., Colloca G. F., Marazzi F., Cornacchione P., Mazzarella C., Masiello V., Chiesa S. (ORCID:0000-0003-0168-3459), Beghella Bartoli F., Marconi E. (ORCID:0000-0001-6722-8390), D'Oria M., Cesario A. (ORCID:0000-0003-4687-0709), Chieffo D. P. R., Valentini V. (ORCID:0000-0003-4637-6487), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Tagliaferri, Luca, Dinapoli, Loredana, Casa, Cristina, Colloca, Giuseppe Ferdinando, Marazzi, Fabio, Cornacchione, Patrizia, Mazzarella, Maria Cristina, Masiello, Valeria, Chiesa, Silvia, Beghella Bartoli, Francesco, Marconi, Elisa, D'Oria, Marika, Cesario, Alfredo, Chieffo, Daniela Pia Rosaria, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Tagliaferri L. (ORCID:0000-0003-2308-0982), Dinapoli L., Casa C., Colloca G. F., Marazzi F., Cornacchione P., Mazzarella C., Masiello V., Chiesa S. (ORCID:0000-0003-0168-3459), Beghella Bartoli F., Marconi E. (ORCID:0000-0001-6722-8390), D'Oria M., Cesario A. (ORCID:0000-0003-4687-0709), Chieffo D. P. R., Valentini V. (ORCID:0000-0003-4637-6487), and Gambacorta M. A. (ORCID:0000-0001-5455-8737)
- Abstract
Introduction: New digital technologies can become a tool for welcoming the patient through the artistic dimension. Cancer patients, in particular, need support that accompanies and supports them throughout their treatment. Materials and methods: The Art4ART project consist in the structural proposal to cancer patients of a web-based digital platform containing several forms of art as video-entertainments; a multimedia immersive room; an art-based welcoming of the patients with several original paintings; an environment with a peacefulness vertical garden; a reconceptualization of the chemotherapy-infusion seats. Data regarding patients’ preference and choices will be stored and analysed also using artificial intelligence (AI) algorithm to measure and predict impact indicators regarding clinical outcomes (survival and toxicity), psychological indicators. Moreover, the same digital platform will contribute to a better organization of the activities. Discussion: Through the systematic acquisition of patient preferences and through integration with other clinical parameters, it will be possible to measure the clinical, psychological, organisational, and social impact of the newly implemented Art4ART project. The use of digital technology leads us to apply the reversal of viewpoint from therapeutic acts to patient-centred care.
- Published
- 2022
5. Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance
- Author
-
Palluzzi, E., Marchetti, Claudia, Cappuccio, S., Avesani, Giacomo, Macchia, Gabriella, Gambacorta, Maria Antonietta, Cocciolillo, F., Scambia, Giovanni, Fagotti, Anna, Marchetti C. (ORCID:0000-0001-7098-8956), Avesani G., Macchia G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Scambia G. (ORCID:0000-0003-2758-1063), Fagotti A. (ORCID:0000-0001-5579-335X), Palluzzi, E., Marchetti, Claudia, Cappuccio, S., Avesani, Giacomo, Macchia, Gabriella, Gambacorta, Maria Antonietta, Cocciolillo, F., Scambia, Giovanni, Fagotti, Anna, Marchetti C. (ORCID:0000-0001-7098-8956), Avesani G., Macchia G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Scambia G. (ORCID:0000-0003-2758-1063), and Fagotti A. (ORCID:0000-0001-5579-335X)
- Abstract
Objective: The benefit of surgery and maintenance treatment with PARP inhibitors (PARPi) has been clearly demonstrated in ovarian cancer. Also, the efficacy and safety of stereotactic body radiotherapy has been shown in patients with metastatic, persistent, and recurrent disease. The aim of this study is to evaluate the management of oligometastatic progression during PARPi maintenance treatment. Methods: This is an observational, retrospective, single-arm study conducted from June 2017 to December 2020 in patients with recurrent ovarian cancer with oligometastatic progression under PARPi maintenance treatment and receiving surgery or stereotactic body radiotherapy for such recurrence. PARPi treatment was continued until further progression of the disease. The primary objective of the study was the median prolongation of the treatment-free interval-p (without platinum) after local treatment. Results: A total of 186 patients with ovarian cancer were treated with PARPi at recurrence. Of these, 30 (16%) developed oligometastatic progression. The median age was 49.5 years (range 35-73). Olaparib, niraparib and rucaparib were administered to 33%, 60%, and 7% of patients, respectively. The median prolongation of the treatment-free interval-p of patients treated with surgery or stereotactic body radiotherapy was 6 and 10 months, respectively (p=0.53). The median treatment-free interval-p of patients treated with surgery or stereotactic body radiotherapy at the time of oligometastatic progression was 32 and 29 months, respectively (p=0.44). At the time of this publication, 50% of patients are still on treatment with PARPi following progression. Conclusions: Patients with recurrent ovarian cancer who have oligometastic progression during PARPi maintenance may continue to benefit from PARPi if combined with local treatment.
- Published
- 2022
6. Project for interventional Oncology LArge-database in liveR Hepatocellular carcinoma - Preliminary CT-based radiomic analysis (POLAR Liver 1.1)
- Author
-
Iezzi, Roberto, Casà, C, Posa, Alessandro, Cornacchione, Patrizia, Carchesio, F, Boldrini, Luca, Tanzilli, A, Cerrito, Lucia, Fionda, B, Longo, V, Miele, Luca, Lancellotta, V, Cellini, Francesco, Tran, H E, Ponziani, Francesca Romana, Giuliante, Felice, Rapaccini, Gian Ludovico, Grieco, Antonio, Pompili, Maurizio, Gasbarrini, Antonio, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Tagliaferri, Luca, Manfredi, Riccardo, Iezzi, R (ORCID:0000-0002-2791-481X), Posa, A, Cornacchione, P, Boldrini, L, Cerrito, L, Miele, L (ORCID:0000-0003-3464-0068), Cellini, F (ORCID:0000-0002-2145-2300), Ponziani, F R (ORCID:0000-0002-5924-6238), Giuliante, F (ORCID:0000-0001-9517-8220), Rapaccini, G L (ORCID:0000-0002-6467-857X), Grieco, A (ORCID:0000-0002-0544-8993), Pompili, M (ORCID:0000-0001-6699-7980), Gasbarrini, A (ORCID:0000-0002-7278-4823), Valentini, V (ORCID:0000-0003-4637-6487), Gambacorta, M A (ORCID:0000-0001-5455-8737), Tagliaferri, L (ORCID:0000-0003-2308-0982), Manfredi, R (ORCID:0000-0002-4972-9500), Iezzi, Roberto, Casà, C, Posa, Alessandro, Cornacchione, Patrizia, Carchesio, F, Boldrini, Luca, Tanzilli, A, Cerrito, Lucia, Fionda, B, Longo, V, Miele, Luca, Lancellotta, V, Cellini, Francesco, Tran, H E, Ponziani, Francesca Romana, Giuliante, Felice, Rapaccini, Gian Ludovico, Grieco, Antonio, Pompili, Maurizio, Gasbarrini, Antonio, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Tagliaferri, Luca, Manfredi, Riccardo, Iezzi, R (ORCID:0000-0002-2791-481X), Posa, A, Cornacchione, P, Boldrini, L, Cerrito, L, Miele, L (ORCID:0000-0003-3464-0068), Cellini, F (ORCID:0000-0002-2145-2300), Ponziani, F R (ORCID:0000-0002-5924-6238), Giuliante, F (ORCID:0000-0001-9517-8220), Rapaccini, G L (ORCID:0000-0002-6467-857X), Grieco, A (ORCID:0000-0002-0544-8993), Pompili, M (ORCID:0000-0001-6699-7980), Gasbarrini, A (ORCID:0000-0002-7278-4823), Valentini, V (ORCID:0000-0003-4637-6487), Gambacorta, M A (ORCID:0000-0001-5455-8737), Tagliaferri, L (ORCID:0000-0003-2308-0982), and Manfredi, R (ORCID:0000-0002-4972-9500)
- Abstract
N/A
- Published
- 2022
7. Radiomics-based prediction of two-year clinical outcome in locally advanced cervical cancer patients undergoing neoadjuvant chemoradiotherapy
- Author
-
Autorino, R., Gui, B., Panza, G., Boldrini, L., Cusumano, D., Russo, L., Nardangeli, A., Persiani, S., Campitelli, M., Ferrandina, G., Macchia, G., Valentini, V., Gambacorta, M. A., Manfredi, R., Autorino R., Gui B., Panza G., Boldrini L., Cusumano D., Russo L., Persiani S., Ferrandina G. (ORCID:0000-0003-4672-4197), Macchia G., Valentini V. (ORCID:0000-0003-4637-6487), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Manfredi R. (ORCID:0000-0002-4972-9500), Autorino, R., Gui, B., Panza, G., Boldrini, L., Cusumano, D., Russo, L., Nardangeli, A., Persiani, S., Campitelli, M., Ferrandina, G., Macchia, G., Valentini, V., Gambacorta, M. A., Manfredi, R., Autorino R., Gui B., Panza G., Boldrini L., Cusumano D., Russo L., Persiani S., Ferrandina G. (ORCID:0000-0003-4672-4197), Macchia G., Valentini V. (ORCID:0000-0003-4637-6487), Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Manfredi R. (ORCID:0000-0002-4972-9500)
- Abstract
Purpose: The aim of this study is to determine if radiomics features extracted from staging magnetic resonance (MR) images could predict 2-year long-term clinical outcome in patients with locally advanced cervical cancer (LACC) after neoadjuvant chemoradiotherapy (NACRT). Materials and methods: We retrospectively enrolled patients with LACC diagnosis who underwent NACRT followed by radical surgery in two different institutions. Radiomics features were extracted from pre-treatment 1.5 T T2w MR images. The predictive performance of each feature was quantified in terms of Wilcoxon–Mann–Whitney test. Among the significant features, Pearson correlation coefficient (PCC) was calculated to quantify the correlation among the different predictors. A logistic regression model was calculated considering the two most significant features at the univariate analysis showing the lowest PCC value. The predictive performance of the model created was quantified out using the area under the receiver operating characteristic curve (AUC). Results: A total of 175 patients were retrospectively enrolled (142 for the training cohort and 33 for the validation one). 1896 radiomic feature were extracted, 91 of which showed significance (p < 0.05) at the univariate analysis. The radiomic model showing the highest predictive value combined the features calculated starting from the gray level co-occurrence-based features. This model achieved an AUC of 0.73 in the training set and 0.91 in the validation set. Conclusions: The proposed radiomic model showed promising performances in predicting 2-year overall survival before NACRT. Nevertheless, the observed results should be tested in larger studies with consistent external validation cohorts, to confirm their potential clinical use.
- Published
- 2022
8. Modern Management of Esophageal Cancer: Radio-Oncology in Neoadjuvancy, Adjuvancy and Palliation
- Author
-
Cellini, Francesco, Manfrida, Stefania, Casa, C., Romano, Angela, Arcelli, A., Zamagni, A., De Luca, V., Colloca, Giuseppe Ferdinando, D'Aviero, A., Fuccio, L., Lancellotta, V., Tagliaferri, Luca, Boldrini, Luca, Mattiucci, Gian Carlo, Gambacorta, Maria Antonietta, Morganti, Alessio Giuseppe, Valentini, Vincenzo, Cellini F. (ORCID:0000-0002-2145-2300), Manfrida S., Romano A., Colloca G. F., Tagliaferri L. (ORCID:0000-0003-2308-0982), Boldrini L., Mattiucci G. C. (ORCID:0000-0001-6500-0413), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Morganti A. G., Valentini V. (ORCID:0000-0003-4637-6487), Cellini, Francesco, Manfrida, Stefania, Casa, C., Romano, Angela, Arcelli, A., Zamagni, A., De Luca, V., Colloca, Giuseppe Ferdinando, D'Aviero, A., Fuccio, L., Lancellotta, V., Tagliaferri, Luca, Boldrini, Luca, Mattiucci, Gian Carlo, Gambacorta, Maria Antonietta, Morganti, Alessio Giuseppe, Valentini, Vincenzo, Cellini F. (ORCID:0000-0002-2145-2300), Manfrida S., Romano A., Colloca G. F., Tagliaferri L. (ORCID:0000-0003-2308-0982), Boldrini L., Mattiucci G. C. (ORCID:0000-0001-6500-0413), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Morganti A. G., and Valentini V. (ORCID:0000-0003-4637-6487)
- Abstract
The modern management of esophageal cancer is crucially based on a multidisciplinary and multimodal approach. Radiotherapy is involved in neoadjuvant and adjuvant settings; moreover, it includes radical and palliative treatment intention (with a focus on the use of a stent and its potential integration with radiotherapy). In this review, the above-mentioned settings and approaches will be described. Referring to available international guidelines, the background evidence bases will be reviewed, and the ongoing, more relevant trials will be outlined. Target definitions and radiotherapy doses to administer will be mentioned. Peculiar applications such as brachytherapy (interventional radiation oncology), and data regarding innovative approaches including MRI-guided-RT and radiomic analysis will be reported. A focus on the avoidance of surgery for major clinical responses (particularly for SCC) is detailed.
- Published
- 2022
9. The impact of radiomics in diagnosis and staging of pancreatic cancer
- Author
-
Casa, Cristina, Piras, A., D'Aviero, A., Preziosi, Francesco, Mariani, Silvia, Cusumano, Davide, Romano, Angela, Boskoski, Ivo, Lenkowicz, Jacopo, Dinapoli, Nicola, Cellini, Francesco, Gambacorta, Maria Antonietta, Valentini, Vincenzo, Mattiucci, Gian Carlo, Boldrini, Luca, Casa C., Preziosi F., Mariani S., Cusumano D., Romano A., Boskoski I. (ORCID:0000-0001-8194-2670), Lenkowicz J., Dinapoli N., Cellini F. (ORCID:0000-0002-2145-2300), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), Mattiucci G. C. (ORCID:0000-0001-6500-0413), Boldrini L., Casa, Cristina, Piras, A., D'Aviero, A., Preziosi, Francesco, Mariani, Silvia, Cusumano, Davide, Romano, Angela, Boskoski, Ivo, Lenkowicz, Jacopo, Dinapoli, Nicola, Cellini, Francesco, Gambacorta, Maria Antonietta, Valentini, Vincenzo, Mattiucci, Gian Carlo, Boldrini, Luca, Casa C., Preziosi F., Mariani S., Cusumano D., Romano A., Boskoski I. (ORCID:0000-0001-8194-2670), Lenkowicz J., Dinapoli N., Cellini F. (ORCID:0000-0002-2145-2300), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), Mattiucci G. C. (ORCID:0000-0001-6500-0413), and Boldrini L.
- Abstract
Introduction: Pancreatic cancer (PC) is one of the most aggressive tumours, and better risk stratification among patients is required to provide tailored treatment. The meaning of radiomics and texture analysis as predictive techniques are not already systematically assessed. The aim of this study is to assess the role of radiomics in PC. Methods: A PubMed/MEDLINE and Embase systematic review was conducted to assess the role of radiomics in PC. The search strategy was ‘radiomics [All Fields] AND (“pancreas” [MeSH Terms] OR “pancreas” [All Fields] OR “pancreatic” [All Fields])’ and only original articles referred to PC in humans in the English language were considered. Results: A total of 123 studies and 183 studies were obtained using the mentioned search strategy on PubMed and Embase, respectively. After the complete selection process, a total of 56 papers were considered eligible for the analysis of the results. Radiomics methods were applied in PC for assessment technical feasibility and reproducibility aspects analysis, risk stratification, biologic or genomic status prediction and treatment response prediction. Discussion: Radiomics seems to be a promising approach to evaluate PC from diagnosis to treatment response prediction. Further and larger studies are required to confirm the role and allowed to include radiomics parameter in a comprehensive decision support system.
- Published
- 2022
10. The Role of Simultaneous Integrated Boost in Locally Advanced Rectal Cancer Patients with Positive Lateral Pelvic Lymph Nodes
- Author
-
Meldolesi, Elisa, Chiloiro, Giuditta, Giannini, Roberta, Menghi, Roberta, Persiani, Roberto, Corvari, B., Coco, Claudio, Manfrida, Stefania, Ratto, Carlo, De Luca, V., Sofo, Luigi, Reina, Sara, Crucitti, Antonio, Masiello, V., Dinapoli, Nicola, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Meldolesi E., Chiloiro G., Giannini R., Menghi R., Persiani R. (ORCID:0000-0002-1537-5097), Coco C. (ORCID:0000-0002-4713-7093), Manfrida S., Ratto C. (ORCID:0000-0002-0556-0037), Sofo L. (ORCID:0000-0002-0592-5999), Reina S., Crucitti A. (ORCID:0000-0003-3496-4185), Dinapoli N., Valentini V. (ORCID:0000-0003-4637-6487), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Meldolesi, Elisa, Chiloiro, Giuditta, Giannini, Roberta, Menghi, Roberta, Persiani, Roberto, Corvari, B., Coco, Claudio, Manfrida, Stefania, Ratto, Carlo, De Luca, V., Sofo, Luigi, Reina, Sara, Crucitti, Antonio, Masiello, V., Dinapoli, Nicola, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Meldolesi E., Chiloiro G., Giannini R., Menghi R., Persiani R. (ORCID:0000-0002-1537-5097), Coco C. (ORCID:0000-0002-4713-7093), Manfrida S., Ratto C. (ORCID:0000-0002-0556-0037), Sofo L. (ORCID:0000-0002-0592-5999), Reina S., Crucitti A. (ORCID:0000-0003-3496-4185), Dinapoli N., Valentini V. (ORCID:0000-0003-4637-6487), and Gambacorta M. A. (ORCID:0000-0001-5455-8737)
- Abstract
Aims: Between 11 to 14% of patients with locally advanced rectal cancer (LARC) have positive lateral pelvic lymph nodes (LPLN) at diagnosis, related to a worse prognosis with a 5-year survival rate between 30 to 40%. The best treatment choice for this group of patients is still a challenge. The optimal radiotherapy (RT) dose for LPLN patients has been investigated. Methods: We retrospectively collected data from LARC patients with LPLN at the primary staging MRI, treated in our center from March 2003 to December 2020. Patients underwent a neoadjuvant concomitant chemo-radiotherapy (CRT) treatment on the primary tumor (T), mesorectum, and pelvic nodes, associated with a fluoride-based chemotherapy. The total reached dose was 45 Gy at 1.8 Gy/fr on the elective sites and 55 Gy at 2.2 Gy/fr on the disease and mesorectum. Patients were divided in two groups based on whether they received a simultaneous integrated RT boost on the LPLN or not. Overall Survival (OS), Disease Free Survival (DFS), Metastasis Free Survival (MFS), and Local Control (LC) were evaluated in the whole group and then compared between the two groups. Results: A total of 176 patients were evaluated: 82 were included in the RT boost group and 94 in the non-RT boost group. The median follow-up period was 57.8 months. All the clinical endpoint (OS, DFS, MFS, LC), resulted were affected by the simultaneous integrated boost on LPLN with a survival rate of 84.7%, 79.5%, 84.1%, and 92%, respectively, in the entire population. From the comparison of the two groups, there was a statistical significance towards the RT boost group with a p < 0.006, 0.030, 0.042, 0.026, respectively. Conclusions: Concomitant radiotherapy boost on positive LPLN has shown to be beneficial on the survival outcomes (OS, DFS, MFR, and LC) in patients with LARC and LPLN. This analysis demonstrates that a higher dose of radiotherapy on positive pelvic lymph nodes led not only to a higher local control but also to a better survival ra
- Published
- 2022
11. THUNDER 2: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI guided radiotherapy
- Author
-
Chiloiro, Giuditta, Cusumano, Davide, Boldrini, Luca, Romano, Angela, Placidi, Lorenzo, Nardini, Matteo, Meldolesi, Elisa, Barbaro, Brunella, Coco, Claudio, Crucitti, Antonio, Persiani, Roberto, Petruzziello, Lucio, Ricci, Riccardo, Salvatore, Lisa, Sofo, Luigi, Alfieri, Sergio, Manfredi, Riccardo, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Chiloiro G., Cusumano D., Boldrini L., Romano A., Placidi L., Nardini M., Meldolesi E., Barbaro B. (ORCID:0000-0002-9638-543X), Coco C. (ORCID:0000-0002-4713-7093), Crucitti A. (ORCID:0000-0003-3496-4185), Persiani R. (ORCID:0000-0002-1537-5097), Petruzziello L., Ricci R. (ORCID:0000-0002-9089-5084), Salvatore L., Sofo L. (ORCID:0000-0002-0592-5999), Alfieri S. (ORCID:0000-0002-0404-724X), Manfredi R. (ORCID:0000-0002-4972-9500), Valentini V. (ORCID:0000-0003-4637-6487), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Chiloiro, Giuditta, Cusumano, Davide, Boldrini, Luca, Romano, Angela, Placidi, Lorenzo, Nardini, Matteo, Meldolesi, Elisa, Barbaro, Brunella, Coco, Claudio, Crucitti, Antonio, Persiani, Roberto, Petruzziello, Lucio, Ricci, Riccardo, Salvatore, Lisa, Sofo, Luigi, Alfieri, Sergio, Manfredi, Riccardo, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Chiloiro G., Cusumano D., Boldrini L., Romano A., Placidi L., Nardini M., Meldolesi E., Barbaro B. (ORCID:0000-0002-9638-543X), Coco C. (ORCID:0000-0002-4713-7093), Crucitti A. (ORCID:0000-0003-3496-4185), Persiani R. (ORCID:0000-0002-1537-5097), Petruzziello L., Ricci R. (ORCID:0000-0002-9089-5084), Salvatore L., Sofo L. (ORCID:0000-0002-0592-5999), Alfieri S. (ORCID:0000-0002-0404-724X), Manfredi R. (ORCID:0000-0002-4972-9500), Valentini V. (ORCID:0000-0003-4637-6487), and Gambacorta M. A. (ORCID:0000-0001-5455-8737)
- Abstract
Background: Neoadjuvant chemoradiation therapy (nCRT) is the standard treatment modality in locally advanced rectal cancer (LARC). Since response to radiotherapy (RT) is dose dependent in rectal cancer, dose escalation may lead to higher complete response rates. The possibility to predict patients who will achieve complete response (CR) is fundamental. Recently, an early tumour regression index (ERI) was introduced to predict pathological CR (pCR) after nCRT in LARC patients. The primary endpoints will be the increase of CR rate and the evaluation of feasibility of delta radiomics-based predictive MRI guided Radiotherapy (MRgRT) model. Methods: Patients affected by LARC cT2-3, N0-2 or cT4 for anal sphincter involvement N0-2a, M0 without high risk features will be enrolled in the trial. Neoadjuvant CRT will be administered using MRgRT. The initial RT treatment will consist in delivering 55 Gy in 25 fractions on Gross Tumor Volume (GTV) plus the corresponding mesorectum and 45 Gy in 25 fractions on the drainage nodes. Chemotherapy with 5-fluoracil (5-FU) or oral capecitabine will be administered continuously. A 0.35 Tesla MRI will be acquired at simulation and every day during MRgRT. At fraction 10, ERI will be calculated: if ERI will be inferior than 13.1, the patient will continue the original treatment; if ERI will be higher than 13.1 the treatment plan will be reoptimized, intensifying the dose to the residual tumor at the 11th fraction to reach 60.1 Gy. At the end of nCRT instrumental examinations are to be performed in order to restage patients. In case of stable disease or progression, the patient will undergo surgery. In case of major or complete clinical response, conservative approaches may be chosen. Patients will be followed up to evaluate toxicity and quality of life. The number of cases to be enrolled will be 63: all the patients will be treated at Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome. Discussion: This clinical tri
- Published
- 2022
12. Multidisciplinary Tumor Board Smart Virtual Assistant in Locally Advanced Cervical Cancer: A Proof of Concept
- Author
-
Macchia, Gabriella, Ferrandina, Maria Gabriella, Patarnello, S., Autorino, Rosa, Masciocchi, Carlotta, Pisapia, V., Calvani, C., Iacomini, C., Cesario, Alfredo, Boldrini, Luca, Gui, Benedetta, Rufini, Vittoria, Gambacorta, Maria Antonietta, Scambia, Giovanni, Valentini, Vincenzo, Macchia G., Ferrandina G. (ORCID:0000-0003-4672-4197), Autorino R., Masciocchi C., Cesario A. (ORCID:0000-0003-4687-0709), Boldrini L., Gui B., Rufini V. (ORCID:0000-0002-2052-8078), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Scambia G. (ORCID:0000-0003-2758-1063), Valentini V. (ORCID:0000-0003-4637-6487), Macchia, Gabriella, Ferrandina, Maria Gabriella, Patarnello, S., Autorino, Rosa, Masciocchi, Carlotta, Pisapia, V., Calvani, C., Iacomini, C., Cesario, Alfredo, Boldrini, Luca, Gui, Benedetta, Rufini, Vittoria, Gambacorta, Maria Antonietta, Scambia, Giovanni, Valentini, Vincenzo, Macchia G., Ferrandina G. (ORCID:0000-0003-4672-4197), Autorino R., Masciocchi C., Cesario A. (ORCID:0000-0003-4687-0709), Boldrini L., Gui B., Rufini V. (ORCID:0000-0002-2052-8078), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Scambia G. (ORCID:0000-0003-2758-1063), and Valentini V. (ORCID:0000-0003-4637-6487)
- Abstract
Aim: The first prototype of the “Multidisciplinary Tumor Board Smart Virtual Assistant” is presented, aimed to (i) Automated classification of clinical stage starting from different free-text diagnostic reports; (ii) Resolution of inconsistencies by identifying controversial cases drawing the clinician’s attention to particular cases worthy for multi-disciplinary discussion; (iii) Support environment for education and knowledge transfer to junior staff; (iv) Integrated data-driven decision making and standardized language and interpretation. Patients and Method: Data from patients affected by Locally Advanced Cervical Cancer (LACC), FIGO stage IB2-IVa, treated between 2015 and 2018 were extracted. Magnetic Resonance (MR), Gynecologic examination under general anesthesia (EAU), and Positron Emission Tomography–Computed Tomography (PET-CT) performed at the time of diagnosis were the items from the Electronic Health Records (eHRs) considered for analysis. An automated extraction of eHR that capture the patient’s data before the diagnosis and then, through Natural Language Processing (NLP), analysis and categorization of all data to transform source information into structured data has been performed. Results: In the first round, the system has been used to retrieve all the eHR for the 96 patients with LACC. The system has been able to classify all patients belonging to the training set and - through the NLP procedures - the clinical features were analyzed and classified for each patient. A second important result was the setup of a predictive model to evaluate the patient’s staging (accuracy of 94%). Lastly, we created a user-oriented operational tool targeting the MTB who are confronted with the challenge of large volumes of patients to be diagnosed in the most accurate way. Conclusion: This is the first proof of concept concerning the possibility of creating a smart virtual assistant for the MTB. A significant benefit could come from the integration of these automate
- Published
- 2022
13. Contact skin radiotherapy (brachytherapy) for the treatment of non-melanoma skin cancers during COVID-19 pandemic
- Author
-
Lancellotta, V., D'Aviero, A., Fionda, B., Di Stefani, Alessandro, Casa, Cristina, Del Regno, L., Gentileschi, Stefano, Colloca, Giuseppe Ferdinando, Rossi, E., Schinzari, Giovanni, Gambacorta, Maria Antonietta, Tagliaferri, Luca, Peris, Ketty, Di Stefani A., Casa C., Gentileschi S. (ORCID:0000-0001-9682-4706), Colloca G. F., Schinzari G. (ORCID:0000-0001-6105-7252), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Tagliaferri L. (ORCID:0000-0003-2308-0982), Peris K. (ORCID:0000-0002-5237-0463), Lancellotta, V., D'Aviero, A., Fionda, B., Di Stefani, Alessandro, Casa, Cristina, Del Regno, L., Gentileschi, Stefano, Colloca, Giuseppe Ferdinando, Rossi, E., Schinzari, Giovanni, Gambacorta, Maria Antonietta, Tagliaferri, Luca, Peris, Ketty, Di Stefani A., Casa C., Gentileschi S. (ORCID:0000-0001-9682-4706), Colloca G. F., Schinzari G. (ORCID:0000-0001-6105-7252), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Tagliaferri L. (ORCID:0000-0003-2308-0982), and Peris K. (ORCID:0000-0002-5237-0463)
- Abstract
In the context of the SARS-CoV-2 pandemic, it is important to ensure the quality of cancer treatment as well as patients and health professionals' safety. Individual-based treatment options should be considered in patients with advanced epithelial skin cancer, who are typically elderly and frail. Aim of this study was to assess feasibility and safety of Contact Skin Radiation Therapy (CSRT) to treat basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) during SARS-CoV-2 pandemic. Patients with advanced and difficult-to-treat BCC or SCC were discussed at skin multidisciplinary tumor board (S-MDTB) from February the 21st to May the 4th (phase 1 Italian Pandemic) and retrospectively analyzed. Patient's triage following internal recommendations was daily performed. CSRT was delivered in 8 fractions of 5 Gy each, twice a day. Beyond the clinical outcomes, treatment success indicators, such as the completion of CSRT without SARS-CoV-2 occurrence, were identified to evaluate the feasibility of CSRT during pandemic. A post-treatment psychological assessment regarding patient's safety perception was performed. Six male patients (median age 80 years; range 62–92) with histologically confirmed BCC or SCC were treated with CSRT. Complete clinical remission was achieved in 5/6 patients (83.4%). No high-grade acute toxicities occurred during treatment. No patients or healthcare personnel developed SARS-CoV-2 infection. All the treatment success indicators were achieved. CSRT represents a safe, and feasible treatment option even during the pandemic emergency period. Hypofractionation could be an option to reduce total number of fractions and, consequently, infective risk exposition.
- Published
- 2022
14. Developing and validating ultrasound-based radiomics models for predicting high-risk endometrial cancer
- Author
-
Moro, Francesca, Albanese, M, Boldrini, Luca, Chiappa, V, Lenkowicz, Jacopo, Bertolina, F, Mascilini, F, Moroni, R, Gambacorta, Maria Antonietta, Raspagliesi, F, Scambia, Giovanni, Testa, Antonia Carla, Fanfani, Francesco, Moro, F, Boldrini, L, Lenkowicz, J, Gambacorta, M A (ORCID:0000-0001-5455-8737), Scambia, G (ORCID:0000-0003-2758-1063), Testa, A C (ORCID:0000-0003-2217-8726), Fanfani, F (ORCID:0000-0003-1991-7284), Moro, Francesca, Albanese, M, Boldrini, Luca, Chiappa, V, Lenkowicz, Jacopo, Bertolina, F, Mascilini, F, Moroni, R, Gambacorta, Maria Antonietta, Raspagliesi, F, Scambia, Giovanni, Testa, Antonia Carla, Fanfani, Francesco, Moro, F, Boldrini, L, Lenkowicz, J, Gambacorta, M A (ORCID:0000-0001-5455-8737), Scambia, G (ORCID:0000-0003-2758-1063), Testa, A C (ORCID:0000-0003-2217-8726), and Fanfani, F (ORCID:0000-0003-1991-7284)
- Abstract
n/a
- Published
- 2022
15. Does restaging MRI radiomics analysis improve pathological complete response prediction in rectal cancer patients? A prognostic model development
- Author
-
Chiloiro, Giuditta, Cusumano, Davide, de Franco, P., Lenkowicz, Jacopo, Boldrini, Luca, Carano, Davide, Barbaro, Brunella, Corvari, B., Dinapoli, Nicola, Giraffa, M., Meldolesi, Elisa, Manfredi, Riccardo, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Chiloiro G., Cusumano D., Lenkowicz J., Boldrini L., Carano D., Barbaro B. (ORCID:0000-0002-9638-543X), Dinapoli N., Meldolesi E., Manfredi R. (ORCID:0000-0002-4972-9500), Valentini V. (ORCID:0000-0003-4637-6487), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Chiloiro, Giuditta, Cusumano, Davide, de Franco, P., Lenkowicz, Jacopo, Boldrini, Luca, Carano, Davide, Barbaro, Brunella, Corvari, B., Dinapoli, Nicola, Giraffa, M., Meldolesi, Elisa, Manfredi, Riccardo, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Chiloiro G., Cusumano D., Lenkowicz J., Boldrini L., Carano D., Barbaro B. (ORCID:0000-0002-9638-543X), Dinapoli N., Meldolesi E., Manfredi R. (ORCID:0000-0002-4972-9500), Valentini V. (ORCID:0000-0003-4637-6487), and Gambacorta M. A. (ORCID:0000-0001-5455-8737)
- Abstract
Purpose: Our study investigated the contribution that the application of radiomics analysis on post-treatment magnetic resonance imaging can add to the assessments performed by an experienced disease-specific multidisciplinary tumor board (MTB) for the prediction of pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC). Materials and methods: This analysis included consecutively retrospective LARC patients who obtained a complete or near-complete response after nCRT and/or a pCR after surgery between January 2010 and September 2019. A three-step radiomics features selection was performed and three models were generated: a radiomics model (rRM), a multidisciplinary tumor board model (yMTB) and a combined model (CM). The predictive performance of models was quantified using the receiver operating characteristic (ROC) curve, evaluating the area under curve (AUC). Results: The analysis involved 144 LARC patients; a total of 232 radiomics features were extracted from the MR images acquired post-nCRT. The yMTB, rRM and CM predicted pCR with an AUC of 0.82, 0.73 and 0.84, respectively. ROC comparison was not significant (p = 0.6) between yMTB and CM. Conclusion: Radiomics analysis showed good performance in identifying complete responders, which increased when combined with standard clinical evaluation; this increase was not statistically significant but did improve the prediction of clinical response.
- Published
- 2022
16. Magnetic resonance–guided radiotherapy feasibility in elderly cancer patients: proposal of the MASTER scoring system
- Author
-
Boldrini, Luca, Colloca, Giuseppe Ferdinando, Villani, Emanuele Rocco, Chiloiro, Giuditta, Bellieni, A., Manfrida, Stefania, Cellini, Francesco, Gambacorta, Maria Antonietta, Valentini, Vincenzo, Boldrini L., Colloca G. F., Villani E., Chiloiro G., Manfrida S., Cellini F. (ORCID:0000-0002-2145-2300), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), Boldrini, Luca, Colloca, Giuseppe Ferdinando, Villani, Emanuele Rocco, Chiloiro, Giuditta, Bellieni, A., Manfrida, Stefania, Cellini, Francesco, Gambacorta, Maria Antonietta, Valentini, Vincenzo, Boldrini L., Colloca G. F., Villani E., Chiloiro G., Manfrida S., Cellini F. (ORCID:0000-0002-2145-2300), Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Valentini V. (ORCID:0000-0003-4637-6487)
- Abstract
Background: Elderly patients are often excluded from advanced treatments owing to clinical complexity or frailty. Magnetic resonance–guided radiotherapy (MRgRT) represents a new frontier of radiotherapy delivery that can play an important role in the management of these patients. Aim: To assess MRgRT feasibility in elderly patients, describe their compliance with this treatment, and provide a scoring system for elderly patient selection. Methods: Patients aged >75 years were enrolled. No restrictions on tumor site, staging, or treatment intent were applied. Patients underwent joint radiation oncology–geriatrics visits to assess the feasibility of MRgRT and to identify the most significant items (i.e. clinical variables) for the setup of a scoring system. The proposed scoring system was then internally validated on a prospectively enrolled cohort of elderly patients who were candidates for MRgRT. Results: Thirty patients were enrolled between February and March 2018. Their mean age was 81.4 ± 3.4 years (range 75–88). Radiotherapy intent was curative in 26 patients; 14 patients were considered frail at screening tests before radiotherapy. Twelve items were identified as clinically significant for the setup of the MASTER score (MRI-Guided Radiotherapy Selection Elderly Score) score. Validation of the score showed 100% reliability, with no patient discharged after selection. Conclusions: MRgRT appears to be feasible in elderly patients and the MASTER score is proposed to support clinical decision-making in recommending elderly patients for this technology.
- Published
- 2021
17. COVID-19 safe and fully operational radiotherapy: An AIRO survey depicting the Italian landscape at the dawn of phase 2
- Author
-
Jereczek-Fossa, B. A., Pepa, M., Zaffaroni, M., Marvaso, G., Bruni, A., Buglione di Monale e Bastia, M., Catalano, G., Filippi, A. R., Franco, P., Gambacorta, M. A., Genovesi, D., Iati, G., Magli, A., Marafioti, L., Meattini, I., Merlotti, A., Mignogna, M., Musio, D., Pacelli, R., Pergolizzi, S., Tombolini, V., Trovo, M., Leonardi, M. C., Ricardi, U., Magrini, S. M., Corvo, R., Donato, V., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Jereczek-Fossa, B. A., Pepa, M., Zaffaroni, M., Marvaso, G., Bruni, A., Buglione di Monale e Bastia, M., Catalano, G., Filippi, A. R., Franco, P., Gambacorta, M. A., Genovesi, D., Iati, G., Magli, A., Marafioti, L., Meattini, I., Merlotti, A., Mignogna, M., Musio, D., Pacelli, R., Pergolizzi, S., Tombolini, V., Trovo, M., Leonardi, M. C., Ricardi, U., Magrini, S. M., Corvo, R., Donato, V., and Gambacorta M. A. (ORCID:0000-0001-5455-8737)
- Abstract
N/A
- Published
- 2021
18. Long-Term Outcomes of Local Excision Following Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
- Author
-
D'Alimonte, L., Bao, Q. R., Spolverato, G., Capelli, Giovanni, Del Bianco, P., Albertoni, L., De Paoli, A., Guerrieri, M., Mantello, G., Gambacorta, Maria Antonietta, Canzonieri, V., Valentini, Vincenzo, Coco, Claudio, Pucciarelli, S., Capelli G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), Coco C. (ORCID:0000-0002-4713-7093), D'Alimonte, L., Bao, Q. R., Spolverato, G., Capelli, Giovanni, Del Bianco, P., Albertoni, L., De Paoli, A., Guerrieri, M., Mantello, G., Gambacorta, Maria Antonietta, Canzonieri, V., Valentini, Vincenzo, Coco, Claudio, Pucciarelli, S., Capelli G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), and Coco C. (ORCID:0000-0002-4713-7093)
- Abstract
Background: Local excision might represent an alternative to total mesorectal excision for patients with locally advanced rectal cancer who achieve a major or complete clinical response after neoadjuvant chemoradiotherapy. Methods: Between August 2005 and July 2011, 63 patients with mid-low rectal adenocarcinoma who had a major/complete clinical response after neoadjuvant chemoradiotherapy were enrolled in a multicenter prospective phase 2 trial and underwent transanal full thickness local excision. The main endpoint of this study was to evaluate the 5- and 10-year overall, relapse-free, local, and distant relapse-free survival, which were calculated by applying the Kaplan–Meier method. The rate of patients with rectum preserved and without stoma were also calculated. Results: Of 63 patients, 38 (60%) were male and 25 (40%) were female, with a median (range) age of 64 (25–82) years. At baseline, the following clinical stages were found: cT2, n = 21 (33.3%); cT3, n = 42 (66.6%), 39 (61.9%) patients were cN+. At a median (range) follow-up of 108 (32–166) months, the estimated cumulative 5- and 10-year overall survival, relapse-free survival, local recurrence-free survival, and distant recurrence-free survival were 87% (95% CI 76–93) and 79% (95% CI 66–87), 89% (95% CI 78–94) and 82% (95% CI 66–91), both 91% (95% CI 81–96), and 90% (95% CI 80–95) and 86% (95% CI 73–93), respectively. Overall, 49 (77.8%) patients had their rectum preserved, and 54 (84.1%) were stoma-free. Conclusion: In highly selected patients, the local excision approach after neoadjuvant chemoradiotherapy is associated with excellent long-term outcomes, high rates of rectum preservation and absence of permanent stoma.
- Published
- 2021
19. Role of neoadjuvant radiochemotherapy for esophageal cancers over pre/peri-operative chemotherapy in the era of COVID-19 and beyond
- Author
-
Cellini, Francesco, Gambacorta, Maria Antonietta, Mattiucci, Gian Carlo, Valentini, Vincenzo, Cellini F. (ORCID:0000-0002-2145-2300), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Mattiucci G. C. (ORCID:0000-0001-6500-0413), Valentini V. (ORCID:0000-0003-4637-6487), Cellini, Francesco, Gambacorta, Maria Antonietta, Mattiucci, Gian Carlo, Valentini, Vincenzo, Cellini F. (ORCID:0000-0002-2145-2300), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Mattiucci G. C. (ORCID:0000-0001-6500-0413), and Valentini V. (ORCID:0000-0003-4637-6487)
- Abstract
N/A
- Published
- 2021
20. Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials
- Author
-
Gambacorta, M. A., Masciocchi, C., Chiloiro, G., Meldolesi, E., Macchia, G., van Soest, J., Peters, F., Collette, L., Gerard, J. -P., Ngan, S., Rodel, C. C., Damiani, A., Dekker, A., Valentini, V., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Masciocchi C., Chiloiro G., Meldolesi E., Macchia G., Damiani A., Valentini V. (ORCID:0000-0003-4637-6487), Gambacorta, M. A., Masciocchi, C., Chiloiro, G., Meldolesi, E., Macchia, G., van Soest, J., Peters, F., Collette, L., Gerard, J. -P., Ngan, S., Rodel, C. C., Damiani, A., Dekker, A., Valentini, V., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Masciocchi C., Chiloiro G., Meldolesi E., Macchia G., Damiani A., and Valentini V. (ORCID:0000-0003-4637-6487)
- Abstract
Purpose: Optimal timing of surgery after neoadjuvant chemoradiotherapy (Nad-CRT) is still controversial in locally advanced rectal cancer (LARC). The primary goal of this study was to determine the best surgical interval (SI) to achieve the highest rate of pathological complete response (pCR) and secondly to evaluate the effect on survival outcomes according to the SI. Patients and methods: Patients data were extracted from the international randomized trials: Accord12/0405, EORTC22921, FFCD9203, CAO/ARO/AIO-94, CAO-ARO-AIO-04, INTERACT and TROG01.04. Inclusion criteria were: age≥ 18, cT3–T4 and cN0–2, no clinical evidence of distant metastasis at diagnosis, Nad-CRT followed by surgery. Pearson's Chi-squared test with Yates’ continuity correction for categorical variables, the Mann–Whitney test for continuous variables, Mann–Kendall test, Kaplan–Meier curves with log-rank test, univariate and multivariate logistic regression model was used for data analysis. Results: 3085 patients met the inclusion criteria. Overall, the pCR rate was 14% at a median SI of 6 weeks (range 1–31). The cumulative pCR rate increased significantly when SI lengthened, with 95% of pCR events within 10 weeks from Nad-CRT. At univariate and multivariate logistic regression analysis, lengthening of SI (p< 0.01), radiotherapy dose (p< 0.01), and the addition of oxaliplatin to Nad-CRT (p< 0.01) had a favorable impact on pCR. Furthermore, lengthening of SI was not impact on local recurrences, distance metastases, and overall survival. Conclusion: This pooled analysis suggests that the best time to achieve pCR in LARC is at 10 weeks, considering that the lengthening of SI is not detrimental concerning survival outcomes.
- Published
- 2021
21. The Multidimensional Assessment for Pediatric Patients in Radiotherapy (M.A.P.-RT) Tool for Customized Treatment Preparation: RADAR Project
- Author
-
Chiesa, Silvia, Marconi, E., Dinapoli, Nicola, Sanfilippo, M. Z., Ruggiero, Antonio, Mastronuzzi, A., Panza, Giulia, Serra, A., Massaccesi, Mariangela, Cacchione, A., Beghella Bartoli, F., Chieffo, D. P. R., Gambacorta, Maria Antonietta, Valentini, Vincenzo, Balducci, Mario, Chiesa S. (ORCID:0000-0003-0168-3459), Dinapoli N., Ruggiero A. (ORCID:0000-0002-6052-3511), Panza G., Massaccesi M., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), Balducci M. (ORCID:0000-0003-0398-9726), Chiesa, Silvia, Marconi, E., Dinapoli, Nicola, Sanfilippo, M. Z., Ruggiero, Antonio, Mastronuzzi, A., Panza, Giulia, Serra, A., Massaccesi, Mariangela, Cacchione, A., Beghella Bartoli, F., Chieffo, D. P. R., Gambacorta, Maria Antonietta, Valentini, Vincenzo, Balducci, Mario, Chiesa S. (ORCID:0000-0003-0168-3459), Dinapoli N., Ruggiero A. (ORCID:0000-0002-6052-3511), Panza G., Massaccesi M., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), and Balducci M. (ORCID:0000-0003-0398-9726)
- Abstract
Aims: Pediatric patients may experience considerable distress during radiotherapy. Combining psychological interventions with standard therapies can reduce the need for sedation. The RADAR Project aims to use a systematic method of recording data that can reveal patients' difficulties and fragility during treatment. In this context, the aim of our study was to investigate the ability of a multidimensional assessment tool (M.A.P.-RT schedule) to predict the need for sedation during radiotherapy. The schedule, which is administered during the first evaluation, was created to collect information on patients and their families in a standardized way. Materials and Methods: The study enrolled pediatric patients (aged 0–18 years or 18–21 with cognitive impairment). Data were collected by means of the M.A.P.-RT module; this explores various thematic areas, and is completed by the radiation oncologist, psychologist and nurse during their first evaluation. Features were selected by means of the Boruta method (random forest classifier), and the totals of the significant partial scores on each subsection of the module were inserted into a logistic model in order to test for their correlation with the use of anesthesia and with the frequency of psychological support. The results of logistic regression (LR) were used to identify the best predictors. The AUC was used to identify the best threshold for the scores in the evaluation. Results: A total of 99 patients were considered for this analysis. The feature that best predicted both the need for anesthesia and the frequency of psychological support was the total score (TS), the AUC of the ROC being 0.9875 for anesthesia and 0.8866 for psychological support. Conclusion: During the first evaluation, the M.A.P.-RT form can predict the need for anesthesia in pediatric patients, and is a potential tool for personalizing therapeutic and management procedures.
- Published
- 2021
22. Perspectives and limits of cancer treatment in an oldest old population
- Author
-
Di Capua, B., Bellieni, A., Fusco, Domenico, Gambacorta, Maria Antonietta, Tagliaferri, Luca, Villani, Emanuele Rocco, Bernabei, Roberto, Valentini, Vincenzo, Colloca, Giuseppe Ferdinando, Fusco D., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Tagliaferri L. (ORCID:0000-0003-2308-0982), Villani E. R., Bernabei R. (ORCID:0000-0002-9197-004X), Valentini V. (ORCID:0000-0003-4637-6487), Colloca G. F., Di Capua, B., Bellieni, A., Fusco, Domenico, Gambacorta, Maria Antonietta, Tagliaferri, Luca, Villani, Emanuele Rocco, Bernabei, Roberto, Valentini, Vincenzo, Colloca, Giuseppe Ferdinando, Fusco D., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Tagliaferri L. (ORCID:0000-0003-2308-0982), Villani E. R., Bernabei R. (ORCID:0000-0002-9197-004X), Valentini V. (ORCID:0000-0003-4637-6487), and Colloca G. F.
- Abstract
Background: Population of oldest old will grow dramatically in the next future and cancer, physiologically related to aging, will be very prevalent among them. Lack of evidence is a huge problem to manage cancer in oldest old and will be more and more in the next years. Aims: Our purpose was to investigate the characteristics of a population of oldest old patients with cancer treated in the Radiation Oncology Unit of Fondazione Policlinico A. Gemelli IRCCS. Methods: We conducted a retrospective study. The primary outcome was to evaluate which characteristics of the population could influence the choice of oncological treatment (with radical or non-radical intent). Results: We identified a total of 348 patients: 140 were on follow-up; 177 were under treatment; 31 were considered not eligible for treatments. Patients under treatment had a high comorbidity index (mean Charlson Comorbidity Index 5.4), and a high prevalence of polypharmacy (mean number of drugs 5.6). More than half (53.1%) was treated with radical intent. Patients treated with radical intent were 1 year younger (87.1 years old vs 88.1 years old), more performant (ECOG 0.7 vs 1.3), and had less prevalence of metastatic neoplasia (6.4% vs 34.9%); comorbidities and drugs did not show differences in the two groups. Conclusion: Oldest old, usually not considered in international guidelines, are treated for oncological disease, often with radical intent. The treatment seems not to be tailored considering comorbidities but on performance status.
- Published
- 2021
23. Preoperative chemoradiotherapy affects postoperative outcomes and functional results in patients treated with transanal endoscopic microsurgery for rectal neoplasms
- Author
-
Rizzo, G., Pafundi, D. P., Sionne, Francesco, D'Agostino, Luca, Pietricola, G., Gambacorta, Maria Antonietta, Valentini, Vincenzo, Coco, Claudio, Sionne F., D'Agostino L., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), Coco C. (ORCID:0000-0002-4713-7093), Rizzo, G., Pafundi, D. P., Sionne, Francesco, D'Agostino, Luca, Pietricola, G., Gambacorta, Maria Antonietta, Valentini, Vincenzo, Coco, Claudio, Sionne F., D'Agostino L., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), and Coco C. (ORCID:0000-0002-4713-7093)
- Abstract
Background: The aim of this study was to quantify the incidence of short-term postoperative complications and functional disorders at 1 year from transanal endoscopic microsurgery (TEM) for rectal neoplasms, to compare patients treated with TEM alone and with TEM after preoperative chemoradiotherapy (CRT) and to analyse factors influencing postoperative morbidity and functional outcomes. Methods: A retrospective study was conducted on all patients treated with TEM for rectal neoplasms at our institution in January 2000–December 2017. Data from a prospectively maintained database were retrospectively analysed. Patients were divided into two groups: adenoma or early rectal cancer (no CRT group) and locally advanced extraperitoneal rectal cancer with major or complete clinical response after preoperative CRT (CRT group). Short-term postoperative mortality and morbidity and the functional results at 1 year were recorded. The two groups were compared, and a statistical analysis of factors influencing postoperative morbidity and functional outcomes was performed. Functional outcome was also evaluated with the low anterior resection syndrome (LARS) score (0–20 no LARS, 21–29 minor LARS and 30–42 major LARS). Results: One hundred and thirteen patients (71 males, 42 females, median age 64 years [range 41–80 years]) were included in the study (46 in the CRT group). The overall postoperative complication rate was 23.0%, lower in the noCRT group (p < 0.001), but only 2.7% were grade ≥ 3. The most frequent complication was suture dehiscence (17.6%), which occurred less frequently in the noCRT group (p < 0.001). At 1 year from TEM, the most frequent symptoms was urgency (11.9%, without significant differences between the CRT group and the noCRT group); the noCRT group experienced a lower rate of soiling than the CRT group (0% vs. 7.7%; p: 0.027). The incidence of LARS was evaluated in 47 patients from May 2012 on and was 21.3% occurring less frequen
- Published
- 2021
24. Correction to: Long-Term Outcomes of Local Excision Following Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer (Annals of Surgical Oncology, (2021), 28, 5, (2801-2808), 10.1245/s10434-020-09243-6)
- Author
-
D'Alimonte, L., Bao, Q. R., Spolverato, G., Capelli, Giovanni, Del Bianco, P., Albertoni, L., De Paoli, A., Guerrieri, M., Mantello, G., Gambacorta, Maria Antonietta, Canzonieri, V., Valentini, Vincenzo, Coco, Claudio, Pucciarelli, S., Capelli G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), Coco C. (ORCID:0000-0002-4713-7093), D'Alimonte, L., Bao, Q. R., Spolverato, G., Capelli, Giovanni, Del Bianco, P., Albertoni, L., De Paoli, A., Guerrieri, M., Mantello, G., Gambacorta, Maria Antonietta, Canzonieri, V., Valentini, Vincenzo, Coco, Claudio, Pucciarelli, S., Capelli G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), and Coco C. (ORCID:0000-0002-4713-7093)
- Abstract
Vincenzo Canzonieri’s affiliations are corrected as reflected here.
- Published
- 2021
25. Patients’ satisfaction by smileintm totems in radiotherapy: A two-year mono-institutional experience
- Author
-
Chiloiro, Giuditta, Romano, A., D'Aviero, A., Dinapoli, L., Zane, Elisa, Tenore, A., Boldrini, Luca, Balducci, Mario, Gambacorta, Maria Antonietta, Mattiucci, Gian Carlo, Malavasi, Pierluigi, Cesario, A., Valentini, Vincenzo, Chiloiro G., Zane E. (ORCID:0000-0001-5897-1000), Boldrini L., Balducci M. (ORCID:0000-0003-0398-9726), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Mattiucci G. C. (ORCID:0000-0001-6500-0413), Malavasi P. (ORCID:0000-0001-8178-967X), Valentini V. (ORCID:0000-0003-4637-6487), Chiloiro, Giuditta, Romano, A., D'Aviero, A., Dinapoli, L., Zane, Elisa, Tenore, A., Boldrini, Luca, Balducci, Mario, Gambacorta, Maria Antonietta, Mattiucci, Gian Carlo, Malavasi, Pierluigi, Cesario, A., Valentini, Vincenzo, Chiloiro G., Zane E. (ORCID:0000-0001-5897-1000), Boldrini L., Balducci M. (ORCID:0000-0003-0398-9726), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Mattiucci G. C. (ORCID:0000-0001-6500-0413), Malavasi P. (ORCID:0000-0001-8178-967X), and Valentini V. (ORCID:0000-0003-4637-6487)
- Abstract
Background: Patient’s satisfaction is recognized as an indicator to monitor quality in healthcare services. Patient-reported experience measures (PREMs) may contribute to create a benchmark of hospital performance by assessing quality and safety in cancer care. Methods: The areas of interest assessed were: patient-centric welcome perception (PCWP), punctuality, professionalism and comfort using the Lean Six Sigma (LSS) methodology. The RAMSI (Radioterapia Amica Mia SmileINTM (SI) My Friend RadiotherapySI), project provided for the placement of SI totems with four push buttons using HappyOrNot technology in a high-volume radiation oncology (RO) department. The SI technology was implemented in the RO department of the Fondazione Policlinico Universitario A. Gemelli IRCCS. SI totems were installed in different areas of the department. The SI Experience Index was collected, analyzed and compared. Weekly and monthly reports were created showing hourly, daily and overall trends. Results: From October 2017 to November 2019, a total of 42,755 votes were recorded: 8687, 10,431, 18,628 and 5009 feedback items were obtained for PCWP, professionalism, punctuality, and comfort, respectively. All areas obtained a SI-approved rate ≥ 8.0 Conclusions: The implementation of the RAMSI system proved to be doable according to the large amount of feedback items collected in a high-volume clinical department. The application of the LSS methodology led to specific corrective actions such as modification of the call-in-clinic system during operations planning. In order to provide healthcare optimization, a multicentric and multispecialty network should be defined in order to set up a benchmark.
- Published
- 2021
26. The role of radiotherapy in Kimura’s disease: a multicenter systematic review of literature
- Author
-
Fionda, B., Loperfido, A., Bussu, F., Lancellotta, V., Casa, C., Vavassori, Andrea, Vicenzi, L., Re, A., Deodato, Francesco, Morganti, Alessio Giuseppe, Gambacorta, Maria Antonietta, Tagliaferri, Luca, Vavassori A., Deodato F. (ORCID:0000-0003-1276-5070), Morganti A. G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Tagliaferri L. (ORCID:0000-0003-2308-0982), Fionda, B., Loperfido, A., Bussu, F., Lancellotta, V., Casa, C., Vavassori, Andrea, Vicenzi, L., Re, A., Deodato, Francesco, Morganti, Alessio Giuseppe, Gambacorta, Maria Antonietta, Tagliaferri, Luca, Vavassori A., Deodato F. (ORCID:0000-0003-1276-5070), Morganti A. G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Tagliaferri L. (ORCID:0000-0003-2308-0982)
- Abstract
– OBJECTIVE: From a clinical point of view, Kimura’s disease is typically characterized by a subcutaneous mass occurring predominantly in the head and neck region. It occurs predominantly in young men of Asian descent, with a peak incidence in the second and third decades of life. However, KD has been also reported in other ethnic groups and in children. The most frequently used local treatments are surgical excision, radiotherapy, and surgical excision followed by radiotherapy. The aim of this multicenter systematic review is to highlight the available literature evidence about the outcome of RT in this setting. MATERIALS AND METHODS: A systematic review of any relevant literature in the principal medical databases, such as PubMed, Scopus and Cochrane library, was conducted. The inclusion criteria were original articles specifically reporting about KD and RT, including both prospective and retrospective studies. RESULTS: We were able to identify 11 studies, published from 1989 to 2021, eligible for inclusion in this review. Overall, data on 124 patients were recorded and are presented in this systematic review. The median recurrence rate, considering all patients, was 11% (ranging from 0% to 41.2%). In seven out of 11 studies, the relapse rate was less than 20%. Moreover, the relapse rate was 0% in four studies. CONCLUSIONS: The results of this multicenter systematic literature review show that evidence on RT of KD is limited and derives only from retrospective studies. In this setting RT seems to be well-tolerated and able to produce very high response rates in unresected lesions and reasonable results in terms of local control both as an exclusive and adjuvant treatment.
- Published
- 2021
27. The radiotherapy role in the multidisciplinary management of locally advanced vulvar cancer: A multidisciplinary vulcan team review
- Author
-
Tagliaferri, Luca, Lancellotta, V., Casa, C., Fragomeni, Simona Maria, Ferioli, M., Gentileschi, Stefano, Caretto, Anna Amelia, Corrado, Giacomo, Gui, Benedetta, Colloca, Giuseppe Ferdinando, Gambacorta, Maria Antonietta, Morganti, Alessio Giuseppe, Garganese, Giorgia, Macchia, Gabriella, Tagliaferri L. (ORCID:0000-0003-2308-0982), Fragomeni S. M., Gentileschi S. (ORCID:0000-0001-9682-4706), Caretto A. A., Corrado G., Gui B., Colloca G. F., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Morganti A. G., Garganese G. (ORCID:0000-0002-4209-5285), Macchia G., Tagliaferri, Luca, Lancellotta, V., Casa, C., Fragomeni, Simona Maria, Ferioli, M., Gentileschi, Stefano, Caretto, Anna Amelia, Corrado, Giacomo, Gui, Benedetta, Colloca, Giuseppe Ferdinando, Gambacorta, Maria Antonietta, Morganti, Alessio Giuseppe, Garganese, Giorgia, Macchia, Gabriella, Tagliaferri L. (ORCID:0000-0003-2308-0982), Fragomeni S. M., Gentileschi S. (ORCID:0000-0001-9682-4706), Caretto A. A., Corrado G., Gui B., Colloca G. F., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Morganti A. G., Garganese G. (ORCID:0000-0002-4209-5285), and Macchia G.
- Abstract
Locally advanced vulvar cancer (LAVC) is a challenging disease, requiring multidisci-plinary management. The aim of this review is to propose an integrated clinical approach including radiotherapy (RT) in the multidisciplinary management of LAVC to customize the treatment. A review of the literature was conducted on PubMed, Scopus, and Cochrane library to acquire all relevant studies on RT in LAVC. Based on the available evidence, RT, with or without concurrent chemotherapy, has a relevant role as adjuvant and exclusive treatment or in the neoadjuvant setting. However, multicentric prospective trials are needed to define the best treatment options based on tumor and patient characteristics. A multidisciplinary and multidimensional assessment can also be useful to identify the most suitable approach, considering patients’ age and comorbidities, in view of a better treatment personalization.
- Published
- 2021
28. Radiotherapy with intensity-modulated (Imrt) techniques in the treatment of anal carcinoma (rainstorm): A multicenter study on behalf of airo (Italian association of radiotherapy and clinical oncology) gastrointestinal study group
- Author
-
Caravatta, L., Mantello, G., Valvo, F., Franco, P., Gasparini, L., Rosa, C., Slim, N., Manfrida, S., De Felice, F., Gerardi, M. A., Vagge, S., Krengli, M., Palazzari, E., Osti, M. F., Gonnelli, A., Catalano, G., Pittoni, P., Ivaldi, G. B., Galardi, A., Lupattelli, M., Rosetto, M. E., Niespolo, R. M., Guido, A., Durante, O., Macchia, G., Munoz, F., El Khouzai, B., Lucido, M. R., Porreca, A., Di Nicola, M., Gambacorta, M. A., Donato, V., Genovesi, D., Manfrida S., Macchia G., Porreca A., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Caravatta, L., Mantello, G., Valvo, F., Franco, P., Gasparini, L., Rosa, C., Slim, N., Manfrida, S., De Felice, F., Gerardi, M. A., Vagge, S., Krengli, M., Palazzari, E., Osti, M. F., Gonnelli, A., Catalano, G., Pittoni, P., Ivaldi, G. B., Galardi, A., Lupattelli, M., Rosetto, M. E., Niespolo, R. M., Guido, A., Durante, O., Macchia, G., Munoz, F., El Khouzai, B., Lucido, M. R., Porreca, A., Di Nicola, M., Gambacorta, M. A., Donato, V., Genovesi, D., Manfrida S., Macchia G., Porreca A., and Gambacorta M. A. (ORCID:0000-0001-5455-8737)
- Abstract
A multi-institutional retrospective study was conducted to evaluate the pattern of care and clinical outcomes of anal cancer patients treated with intensity-modulated radiotherapy (IMRT) techniques. In a cohort of 987 patients, the clinical complete response (CR) rate (beyond 6 months) was 90.6%. The 3-year local control (LC) rate was 85.8% (95% CI: 84.4–87.2), and the 3-year colostomy-free survival (CFS) rate was 77.9% (95% CI: 76.1–79.8). Three-year progression-free survival (PFS) and overall survival (OS) rates were 80.2% and 88.1% (95% CI: 78.8–89.4) (95% CI: 78.5–81.9), respectively. Histological grade 3 and nodal involvement were associated with lower CR (p = 0.030 and p = 0.004, respectively). A statistically significant association was found between advanced stage and nodal involvement, and LC, CFS, PFS, OS and event-free survival (EFS). Overall treatment time (OTT) ≥45 days showed a trend for a lower PFS (p = 0.050) and was significantly associated with lower EFS (p = 0.030) and histological grade 3 with a lower LC (p = 0.025). No statistically significant association was found between total dose, dose/fraction and/or boost modality and clinical outcomes. This analysis reports excellent clinical results and a mild toxicity profile, confirming IMRT techniques as standard of care for the curative treatment of anal cancer patients. Lymph node involvement and histological grade have been confirmed as the most important negative prognostic factors.
- Published
- 2021
29. The “PC-WIRED” study: Patient Centred Evolution of Websites of Italian Radiotherapy Departments
- Author
-
Fionda, B., Piras, A., D'Aviero, A., Venuti, V., Casa, C., Preziosi, Francesco, Catucci, F., Boldrini, Luca, Daidone, A., Tagliaferri, Luca, Gambacorta, Maria Antonietta, Valentini, Vincenzo, Preziosi F., Boldrini L., Tagliaferri L. (ORCID:0000-0003-2308-0982), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), Fionda, B., Piras, A., D'Aviero, A., Venuti, V., Casa, C., Preziosi, Francesco, Catucci, F., Boldrini, Luca, Daidone, A., Tagliaferri, Luca, Gambacorta, Maria Antonietta, Valentini, Vincenzo, Preziosi F., Boldrini L., Tagliaferri L. (ORCID:0000-0003-2308-0982), Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Valentini V. (ORCID:0000-0003-4637-6487)
- Abstract
N/A
- Published
- 2021
30. A field strength independent MR radiomics model to predict pathological complete response in locally advanced rectal cancer
- Author
-
Cusumano, Davide, Meijer, G., Lenkowicz, Jacopo, Chiloiro, Giuditta, Boldrini, Luca, Masciocchi, Carlotta, Dinapoli, Nicola, Gatta, Roberto, Casa, C., Damiani, Andrea, Barbaro, Brunella, Gambacorta, Maria Antonietta, Azario, Luigi, De Spirito, Marco, Intven, M., Valentini, Vincenzo, Cusumano D., Lenkowicz J., Chiloiro G., Boldrini L., Masciocchi C., Dinapoli N., Gatta R., Damiani A., Barbaro B. (ORCID:0000-0002-9638-543X), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Azario L. (ORCID:0000-0001-8575-8627), De Spirito M. (ORCID:0000-0003-4260-5107), Valentini V. (ORCID:0000-0003-4637-6487), Cusumano, Davide, Meijer, G., Lenkowicz, Jacopo, Chiloiro, Giuditta, Boldrini, Luca, Masciocchi, Carlotta, Dinapoli, Nicola, Gatta, Roberto, Casa, C., Damiani, Andrea, Barbaro, Brunella, Gambacorta, Maria Antonietta, Azario, Luigi, De Spirito, Marco, Intven, M., Valentini, Vincenzo, Cusumano D., Lenkowicz J., Chiloiro G., Boldrini L., Masciocchi C., Dinapoli N., Gatta R., Damiani A., Barbaro B. (ORCID:0000-0002-9638-543X), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Azario L. (ORCID:0000-0001-8575-8627), De Spirito M. (ORCID:0000-0003-4260-5107), and Valentini V. (ORCID:0000-0003-4637-6487)
- Abstract
Purpose: Aim of this study was to develop a generalised radiomics model for predicting pathological complete response after neoadjuvant chemo-radiotherapy in locally advanced rectal cancer patients using pre-CRT T2-weighted images acquired at a 1.5 T and a 3 T scanner. Methods: In two institutions, 195 patients were scanned: 136 patients were scanned on a 1.5 T MR scanner, 59 patients on a 3 T MR scanner. Gross tumour volumes were delineated on the MR images and 496 radiomic features were extracted, applying the intensity-based (IB) filter. Features were standardised with Z-score normalisation and an initial feature selection was carried out using Wilcoxon–Mann–Whitney test: The most significant features at 1.5 T and 3 T were selected as main features. Several logistic regression models combining the main features with a third one selected by those resulting significant were elaborated and evaluated in terms of area under curve (AUC). A tenfold cross-validation was repeated 300 times to evaluate the model robustness. Results: Three features were selected: maximum fractal dimension with IB = 0–50, energy and grey-level non-uniformity calculated on the run-length matrix with IB = 0–50. The AUC of the model applied to the whole dataset after cross-validation was 0.72, while values of 0.70 and 0.83 were obtained when 1.5 T and 3 T patients were considered, respectively. Conclusions: The model elaborated showed good performance, even when data from patients scanned on 1.5 T and 3 T were merged. This shows that magnetic field intensity variability can be overcome by means of selecting appropriate image features.
- Published
- 2021
31. Could the conservative approach be considered safe in the treatment of locally advanced rectal cancer in case of a clinical near-complete or complete response? A retrospective analysis
- Author
-
Chiloiro, Giuditta, Meldolesi, Elisa, Giraffa, M., Capocchiano, Nikola Dino, Barbaro, Brunella, Coco, Claudio, Corvari, B., De Franco, P., D'Ugo, Domenico, Alfieri, Sergio, Manfredi, Riccardo, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Chiloiro G., Meldolesi E., Capocchiano N. D., Barbaro B. (ORCID:0000-0002-9638-543X), Coco C. (ORCID:0000-0002-4713-7093), D'Ugo D. (ORCID:0000-0001-6657-6318), Alfieri S. (ORCID:0000-0002-0404-724X), Manfredi R. (ORCID:0000-0002-4972-9500), Valentini V. (ORCID:0000-0003-4637-6487), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Chiloiro, Giuditta, Meldolesi, Elisa, Giraffa, M., Capocchiano, Nikola Dino, Barbaro, Brunella, Coco, Claudio, Corvari, B., De Franco, P., D'Ugo, Domenico, Alfieri, Sergio, Manfredi, Riccardo, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Chiloiro G., Meldolesi E., Capocchiano N. D., Barbaro B. (ORCID:0000-0002-9638-543X), Coco C. (ORCID:0000-0002-4713-7093), D'Ugo D. (ORCID:0000-0001-6657-6318), Alfieri S. (ORCID:0000-0002-0404-724X), Manfredi R. (ORCID:0000-0002-4972-9500), Valentini V. (ORCID:0000-0003-4637-6487), and Gambacorta M. A. (ORCID:0000-0001-5455-8737)
- Abstract
Background: Conservative approach has emerged as an option for the management of rectal cancer (RC) patients with a near or complete clinical response after neoadjuvant chemoradiotherapy (nCRT). The aim of this study is to assess the impact of the conservative approach by comparing patients’ survival outcomes and quality of life with those who had surgical resection. Methods: A single-institution and retrospective study including RC patients who reached a near complete or complete clinical response after nCRT from January 2010 to September 2019. Conservative approaches included local excision or watch and wait strategy; surgery approaches included anterior resection or abdominal-perineal resection. Local regrowth (LR), overall survival, disease free survival, metastasis free survival and colostomy free survival were evaluated through Kaplan-Meier curves and compared trough log-rank tests. Quality of life was measured by the following validated questionnaires: EORTC QLC30, EORTC QLQ – CR29 and Fecal Incontinence Quality of Life scale. Results: Overall 157 patients were analyzed: 105 (66,9%) underwent radical surgery and 52 (33,1%) had a conservative approach. With a median follow-up of 51 months, 2 patients in the surgical group had a local recurrence and 8 in the conservative group had a LR, respectively. Distance metastasis occurred in 7 and 1 patients of surgical and conservative group, respectively. No differences were detected in terms of survival outcomes except for colostomy free survival (p: 0,01). The conservative group showed better intestinal (p < 0.01) and sexual (p: 0,04) function and emotional status (p: 0,02). Conclusions: Conservative approach seems to be safe in terms of survival outcomes with a significant advantage on quality of life in RC patients who achieved clinical complete response after nCRT.
- Published
- 2021
32. The role of brachytherapy (interventional radiotherapy) for primary and/or recurrent vulvar cancer: a Gemelli Vul.Can multidisciplinary team systematic review
- Author
-
Lancellotta, V., Macchia, G., Garganese, G., Fionda, B., Fragomeni, S. M., D'Aviero, A., Casa, C., Gui, B., Gentileschi, S., Corrado, G., Inzani, F., Rovirosa, A., Morganti, A. G., Gambacorta, M. A., Tagliaferri, L., Macchia G., Garganese G. (ORCID:0000-0002-4209-5285), Fragomeni S. M., Gui B., Gentileschi S. (ORCID:0000-0001-9682-4706), Inzani F., Morganti A. G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Tagliaferri L. (ORCID:0000-0003-2308-0982), Lancellotta, V., Macchia, G., Garganese, G., Fionda, B., Fragomeni, S. M., D'Aviero, A., Casa, C., Gui, B., Gentileschi, S., Corrado, G., Inzani, F., Rovirosa, A., Morganti, A. G., Gambacorta, M. A., Tagliaferri, L., Macchia G., Garganese G. (ORCID:0000-0002-4209-5285), Fragomeni S. M., Gui B., Gentileschi S. (ORCID:0000-0001-9682-4706), Inzani F., Morganti A. G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Tagliaferri L. (ORCID:0000-0003-2308-0982)
- Abstract
Objective: The aim of our systematic review was to assess the role of interventional radiotherapy (IRT, brachytherapy) in the management of primary and/or recurrent vulvar carcinoma. Evidence acquisition: A systematic research using PubMed, Scopus and Cochrane library was performed. ClinicalTrials.gov was searched for ongoing or recently completed trials, and PROSPERO was searched for ongoing or recently completed systematic reviews. Only full-text English-language articles related to IRT for treatment of primary or recurrent VC were identified and reviewed. Conference paper, survey, letter, editorial, book chapter and review were excluded. Time restriction (1990–2018) as concerns the years of the publication was considered. Evidence synthesis: Primary disease: the median 5-year LC was 43.5% (range 19–68%); the median 5-year DFS was 44.5% (range 44–81%); the median 5-year OS was 50.5% (range 27–85%). Recurrent disease: the median 5-year DFS was 64% (range 56–72%) and the median 5-year OS was 45% (range 33%-57%). Acute ≥ grade 2 toxicity was reported in three patients (1.6%). The severe late toxicity rates (grade 3–4) ranged from 0% to 14.3% (median 7.7%). Conclusion: IRT as part of primary treatment for primary and/or recurrent vulvar cancer is associated with promising clinical outcomes.
- Published
- 2021
33. Pretreatment mri radiomics based response prediction model in locally advanced cervical cancer
- Author
-
Gui, Benedetta, Autorino, Rosa, Micco, M., Nardangeli, A., Pesce, A., Lenkowicz, Jacopo, Cusumano, Davide, Russo, Luca, Persiani, Salvatore, Boldrini, Luca, Dinapoli, Nicola, Macchia, Gabriella, Sallustio, Giuseppina, Gambacorta, Maria Antonietta, Ferrandina, Maria Gabriella, Manfredi, Riccardo, Valentini, Vincenzo, Scambia, G., Gui B., Autorino R., Lenkowicz J., Cusumano D., Russo L., Persiani S., Boldrini L., Dinapoli N., Macchia G., Sallustio G. (ORCID:0000-0002-6641-4914), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Ferrandina G. (ORCID:0000-0003-4672-4197), Manfredi R. (ORCID:0000-0002-4972-9500), Valentini V. (ORCID:0000-0003-4637-6487), Gui, Benedetta, Autorino, Rosa, Micco, M., Nardangeli, A., Pesce, A., Lenkowicz, Jacopo, Cusumano, Davide, Russo, Luca, Persiani, Salvatore, Boldrini, Luca, Dinapoli, Nicola, Macchia, Gabriella, Sallustio, Giuseppina, Gambacorta, Maria Antonietta, Ferrandina, Maria Gabriella, Manfredi, Riccardo, Valentini, Vincenzo, Scambia, G., Gui B., Autorino R., Lenkowicz J., Cusumano D., Russo L., Persiani S., Boldrini L., Dinapoli N., Macchia G., Sallustio G. (ORCID:0000-0002-6641-4914), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Ferrandina G. (ORCID:0000-0003-4672-4197), Manfredi R. (ORCID:0000-0002-4972-9500), and Valentini V. (ORCID:0000-0003-4637-6487)
- Abstract
The aim of this study was to create a radiomics model for Locally Advanced Cervical Cancer (LACC) patients to predict pathological complete response (pCR) after neoadjuvant chemora-diotherapy (NACRT) analysing T2-weighted 1.5 T magnetic resonance imaging (MRI) acquired before treatment start. Patients with LACC and an International Federation of Gynecology and Obstetrics stage from IB2 to IVA at diagnosis were retrospectively enrolled for this study. All patients underwent NACRT, followed by radical surgery; pCR—assessed on surgical specimen—was defined as absence of any residual tumour. Finally, 1889 features were extracted from MR images; features showing statistical significance in predicting pCR at the univariate analysis were selected following an iterative method, which was ad-hoc developed for this study. Based on this method, 15 different classifiers were trained considering the most significant features selected. Model selection was carried out using the area under the receiver operating characteristic curve (AUC) as target metrics. One hundred eighty-three patients from two institutions were analysed. The model, showing the highest performance with an AUC of 0.80, was the random forest method initialised with default parameters. Radiomics appeared to be a reliable tool in pCR prediction for LACC patients undergoing NACRT, supporting the identification of patient risk groups, which paves treatment pathways tailored according to the predicted outcome.
- Published
- 2021
34. Successful Treatment of Tumor-Induced Osteomalacia by Multidisciplinary Therapy with Radiation to Intracranial Fibromyxoid Tumor
- Author
-
Massaccesi, Mariangela, Micciche, F., Rigante, Mario, Petrone, Gianluigi, Lepre, Elisabetta, Gambacorta, Maria Antonietta, Valentini, Vincenzo, Massaccesi M., Rigante M. (ORCID:0000-0002-6111-0786), Petrone G., Lepre E., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), Massaccesi, Mariangela, Micciche, F., Rigante, Mario, Petrone, Gianluigi, Lepre, Elisabetta, Gambacorta, Maria Antonietta, Valentini, Vincenzo, Massaccesi M., Rigante M. (ORCID:0000-0002-6111-0786), Petrone G., Lepre E., Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Valentini V. (ORCID:0000-0003-4637-6487)
- Abstract
Background. Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by protein fibroblast-growth-factor-23 (FGF-23) secreting tumors. Complete tumor resection is the current standard of care for TIO; however, some patients may develop tumor recurrence. Due to the rarity of this paraneoplastic syndrome, the role of radiotherapy is unclear. This case is worth reporting because it adds to our knowledge some insights about the potential role of radiotherapy in this rare condition. Case Presentation. After multidisciplinary consultation, in July 2015, postoperative adjuvant radiotherapy was offered to a 52-year-old man with a multiple recurrent ossifying fibromyxoid tumor in the right frontal sinus causing TIO. The patient had a history of multiple bone fractures and pain since more than 20 years. The tumor had been removed in 2003 for the first time. Subsequent endoscopic resections of the tumor had been performed for recurrences of TIO in May 2012, October 2013, and July 2015. Starting from October 2015, external beam radiotherapy was delivered with a volumetric modulated arc technique to the tumor bed with a daily dose of 2 Gy up to a total dose of 60 Gy. After five years from treatment, the patient is free from local tumor relapse, TIO progression, and radiation-induced side effects. Conclusions. Radiotherapy may provide long-term TIO remission and tumor control, thus being a treatment option in cases where surgery is unfeasible or unsuccessful.
- Published
- 2021
35. A radiotherapy staff experience of gratitude during COVID-19 pandemic
- Author
-
Marconi, E., Chiesa, Silvia, Dinapoli, L., Lepre, Elisabetta, Tagliaferri, Luca, Balducci, Mario, Frascino, Vincenzo, Casa, C., Chieffo, Daniela Pia Rosaria, Gambacorta, Maria Antonietta, Valentini, Vincenzo, Chiesa S. (ORCID:0000-0003-0168-3459), Lepre E., Tagliaferri L. (ORCID:0000-0003-2308-0982), Balducci M. (ORCID:0000-0003-0398-9726), Frascino V., Chieffo D. P. R., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), Marconi, E., Chiesa, Silvia, Dinapoli, L., Lepre, Elisabetta, Tagliaferri, Luca, Balducci, Mario, Frascino, Vincenzo, Casa, C., Chieffo, Daniela Pia Rosaria, Gambacorta, Maria Antonietta, Valentini, Vincenzo, Chiesa S. (ORCID:0000-0003-0168-3459), Lepre E., Tagliaferri L. (ORCID:0000-0003-2308-0982), Balducci M. (ORCID:0000-0003-0398-9726), Frascino V., Chieffo D. P. R., Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Valentini V. (ORCID:0000-0003-4637-6487)
- Abstract
N/A
- Published
- 2021
36. Radiotherapy for benign disorders: Current use in clinical practice
- Author
-
Fionda, B., Lancellotta, V., Casa, C., Boldrini, L., Marazzi, F., Cellini, F., Kovacs, G., Gambacorta, M. A., Tagliaferri, L., Boldrini L., Marazzi F., Cellini F. (ORCID:0000-0002-2145-2300), Kovacs G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Tagliaferri L. (ORCID:0000-0003-2308-0982), Fionda, B., Lancellotta, V., Casa, C., Boldrini, L., Marazzi, F., Cellini, F., Kovacs, G., Gambacorta, M. A., Tagliaferri, L., Boldrini L., Marazzi F., Cellini F. (ORCID:0000-0002-2145-2300), Kovacs G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Tagliaferri L. (ORCID:0000-0003-2308-0982)
- Abstract
Objective: The aim of this paper is to provide an update about the current clinical indications of RT in this poorly explored field outside the traditional oncological setting. Materials and Methods: We performed a literature search on the main databases, including PubMed, Scopus and Cochrane from their inception until 31stDecember 2020. An additional manual check of scientific meeting proceedings and books was conducted in order to identify all the potentially useful sources. Only essays published in English have been considered for the purposes of this analysis. The searched items included: "Radiotherapy or Radiation Therapy" and "Benign disorder or Benign disease". Results: We provided a list of current clinical indications for benign disorders based on the latest international surveys available, including major sites: eye, bone, head and neck, skin, brain, heart and peripheral vascular system. Conclusions: Radiotherapy for benign diseases is still a feasible therapeutic strategy, which may allow to treat several invalidating conditions, especially after medical therapies have failed thus avoiding potentially invalidating major surgical procedures. A careful evaluation in selecting the indication is essential and all the choices should be thoroughly discussed with the patients.
- Published
- 2021
37. Palliative radiotherapy indications during the COVID-19 pandemic and in future complex logistic settings: the NORMALITY model
- Author
-
Cellini, Francesco, Di Franco, R., Manfrida, Stefania, Borzillo, V., Maranzano, E., Pergolizzi, S., Morganti, Alessio Giuseppe, Fusco, Vincenzo, Deodato, Francesco, Santarelli, M., Arcidiacono, F., Rossi, R., Reina, Sara, Merlotti, A., Jereczek-Fossa, B. A., Tozzi, A., Siepe, G., Cacciola, A., Russi, E., Gambacorta, Maria Antonietta, Scorsetti, M., Ricardi, U., Corvo, R., Donato, V., Muto, P., Valentini, Vincenzo, Cellini F. (ORCID:0000-0002-2145-2300), Manfrida S., Morganti A. G., Fusco V., Deodato F. (ORCID:0000-0003-1276-5070), Reina S., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), Cellini, Francesco, Di Franco, R., Manfrida, Stefania, Borzillo, V., Maranzano, E., Pergolizzi, S., Morganti, Alessio Giuseppe, Fusco, Vincenzo, Deodato, Francesco, Santarelli, M., Arcidiacono, F., Rossi, R., Reina, Sara, Merlotti, A., Jereczek-Fossa, B. A., Tozzi, A., Siepe, G., Cacciola, A., Russi, E., Gambacorta, Maria Antonietta, Scorsetti, M., Ricardi, U., Corvo, R., Donato, V., Muto, P., Valentini, Vincenzo, Cellini F. (ORCID:0000-0002-2145-2300), Manfrida S., Morganti A. G., Fusco V., Deodato F. (ORCID:0000-0003-1276-5070), Reina S., Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Valentini V. (ORCID:0000-0003-4637-6487)
- Abstract
Introduction: The COVID-19 pandemic has challenged healthcare systems worldwide over the last few months, and it continues to do so. Although some restrictions are being removed, it is not certain when the pandemic is going to be definitively over. Pandemics can be seen as a highly complex logistic scenario. From this perspective, some of the indications provided for palliative radiotherapy (PRT) during the COVID-19 pandemic could be maintained in the future in settings that limit the possibility of patients achieving symptom relief by radiotherapy. This paper has two aims: (1) to provide a summary of the indications for PRT during the COVID-19 pandemic; since some indications can differ slightly, and to avoid any possible contradictions, an expert panel composed of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) and the Palliative Care and Supportive Therapies Working Group (AIRO-palliative) voted by consensus on the summary; (2) to introduce a clinical care model for PRT [endorsed by AIRO and by a spontaneous Italian collaborative network for PRT named “La Rete del Sollievo” (“The Net of Relief”)]. The proposed model, denoted “No cOmpRoMise on quality of life by pALliative radiotherapy” (NORMALITY), is based on an AIRO-palliative consensus-based list of clinical indications for PRT and on practical suggestions regarding the management of patients potentially suitable for PRT but dealing with highly complex logistics scenarios (similar to the ongoing logistics limits due to COVID-19). Material and Methods: First, a summary of the available literature guidelines for PRT published during the COVID-19 pandemic was prepared. A systematic literature search based on the PRISMA approach was performed to retrieve the available literature reporting guideline indications fully or partially focused on PRT. Tables reporting each addressed clinical presentation and respective literature indications were prepared and distributed into two main groups: palliat
- Published
- 2021
38. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer
- Author
-
Fokas, E., Appelt, A., Glynne-Jones, R., Beets, G., Perez, R., Garcia-Aguilar, J., Rullier, E., Joshua Smith, J., Marijnen, C., Peters, F. P., van der Valk, M., Beets-Tan, R., Myint, A. S., Gerard, J. -P., Bach, S. P., Ghadimi, M., Hofheinz, R. D., Bujko, K., Gani, C., Haustermans, K., Minsky, B. D., Ludmir, E., West, N. P., Gambacorta, Maria Antonietta, Valentini, Vincenzo, Buyse, M., Renehan, A. G., Gilbert, A., Sebag-Montefiore, D., Rodel, C., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), Fokas, E., Appelt, A., Glynne-Jones, R., Beets, G., Perez, R., Garcia-Aguilar, J., Rullier, E., Joshua Smith, J., Marijnen, C., Peters, F. P., van der Valk, M., Beets-Tan, R., Myint, A. S., Gerard, J. -P., Bach, S. P., Ghadimi, M., Hofheinz, R. D., Bujko, K., Gani, C., Haustermans, K., Minsky, B. D., Ludmir, E., West, N. P., Gambacorta, Maria Antonietta, Valentini, Vincenzo, Buyse, M., Renehan, A. G., Gilbert, A., Sebag-Montefiore, D., Rodel, C., Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Valentini V. (ORCID:0000-0003-4637-6487)
- Abstract
Multimodal treatment strategies for patients with rectal cancer are increasingly including the possibility of organ preservation, through nonoperative management or local excision. Organ preservation strategies can enable patients with a complete response or near-complete clinical responses after radiotherapy with or without concomitant chemotherapy to safely avoid the morbidities associated with radical surgery, and thus to maintain anorectal function and quality of life. However, standardization of the key outcome measures of organ preservation strategies is currently lacking; this includes a lack of consensus of the optimal definitions and selection of primary end points according to the trial phase and design; the optimal time points for response assessment; response-based decision-making; follow-up schedules; use of specific anorectal function tests; and quality of life and patient-reported outcomes. Thus, a consensus statement on outcome measures is necessary to ensure consistency and facilitate more accurate comparisons of data from ongoing and future trials. Here, we have convened an international group of experts with extensive experience in the management of patients with rectal cancer, including organ preservation approaches, and used a Delphi process to establish the first international consensus recommendations for key outcome measures of organ preservation, in an attempt to standardize the reporting of data from both trials and routine practice in this emerging area.
- Published
- 2021
39. MRI-guided stereotactic radiation therapy for hepatocellular carcinoma: a feasible and safe innovative treatment approach
- Author
-
Boldrini, L., Romano, A., Mariani, S., Cusumano, D., Catucci, F., Placidi, L., Mattiucci, G. C., Chiloiro, G., Cellini, F., Gambacorta, M. A., Indovina, L., Valentini, V., Boldrini L., Mariani S., Cusumano D., Placidi L., Mattiucci G. C. (ORCID:0000-0001-6500-0413), Chiloiro G., Cellini F. (ORCID:0000-0002-2145-2300), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), Boldrini, L., Romano, A., Mariani, S., Cusumano, D., Catucci, F., Placidi, L., Mattiucci, G. C., Chiloiro, G., Cellini, F., Gambacorta, M. A., Indovina, L., Valentini, V., Boldrini L., Mariani S., Cusumano D., Placidi L., Mattiucci G. C. (ORCID:0000-0001-6500-0413), Chiloiro G., Cellini F. (ORCID:0000-0002-2145-2300), Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Valentini V. (ORCID:0000-0003-4637-6487)
- Abstract
Purpose: Hepatocellular carcinoma (HCC) in early stages benefits from local ablative treatments such as radiofrequency ablation (RFA) or transarterial chemoembolization (TACE). In this context, radiotherapy (RT) has shown promising results but has not been thoroughly evaluated. Magnetic resonance-guided RT (MRgRT) may represent a paradigm shifting improvement in stereotactic body radiotherapy (SBRT) for liver tumors. Methods: We retrospectively evaluated HCC patients treated on a hybrid low-tesla MRgRT unit. A total biologically effective dose (BED) > 100 Gy was delivered in 5 consecutive fractions, respecting the appropriate organs-at-risk constraints. Hybrid MR scans were used for treatment planning and cine MR was used for delivery gating. Patients were followed up for toxicity and treatment–response assessment. Results: Ten patients were enrolled, with a total of 12 lesions. All the lesions were irradiated with no interruptions. Six patients had already performed previous local therapies. Median follow-up after SBRT was 6.5 months (1–25). Two cases of acute toxicity were reported (G ≤ 2 according to CTCAE v4.0). At the time of the analysis, 90% of the population presented local control. Child–Pugh before and after treatment remained unchanged in all but one patient. Conclusion: MRgRT is a feasible and safe option showing favorable toxicity profile for HCC treatment.
- Published
- 2021
40. Unconventional radiotherapy to enhance immunotherapy efficacy in bulky tumors: a case report
- Author
-
Massaccesi, Mariangela, Boldrini, Luca, Romano, A., Rossi, E., Schinzari, Giovanni, Lepre, Elisabetta, Gambacorta, Maria Antonietta, Valentini, Vincenzo, Massaccesi M., Boldrini L., Schinzari G. (ORCID:0000-0001-6105-7252), Lepre E., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), Massaccesi, Mariangela, Boldrini, Luca, Romano, A., Rossi, E., Schinzari, Giovanni, Lepre, Elisabetta, Gambacorta, Maria Antonietta, Valentini, Vincenzo, Massaccesi M., Boldrini L., Schinzari G. (ORCID:0000-0001-6105-7252), Lepre E., Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Valentini V. (ORCID:0000-0003-4637-6487)
- Abstract
Determining the most appropriate management strategy for patients with large tumor masses is a very challenging issue. Unconventional radiotherapy modalities, such as spatially fractionated radiation therapy (SFRT), are associated with dramatic responses. Recent studies have suggested that systemic immune activation may be triggered by SFRT delivery to primary tumor lesion. This report describes the case of a patient treated with a novel form of immune-sparing partially ablative irradiation (ISPART) for a bulky peritoneal metastasis from renal cell cancer, refractory to anti-PD-1 therapy (nivolumab) as third-line therapy after sequential therapy with sunitinib and cabozantinib. The observed response suggests that there may be a synergistic effect between ISPART and immunotherapy. This case report supports the inclusion of ISPART in patients presenting with bulky lesions treated with checkpoint inhibitors.
- Published
- 2021
41. The role of brachytherapy (interventional radiotherapy) for primary and/or recurrent vulvar cancer: a Gemelli Vul.Can multidisciplinary team systematic review
- Author
-
Lancellotta, V., Macchia, Gabriella, Garganese, Giorgia, Fionda, B., Fragomeni, Simona Maria, D'Aviero, Andrea, Casa, C., Gui, Benedetta, Gentileschi, Stefano, Corrado, Giacomo, Inzani, Frediano, Rovirosa, A., Morganti, Alessio Giuseppe, Gambacorta, Maria Antonietta, Tagliaferri, Luca, Macchia G., Garganese G. (ORCID:0000-0002-4209-5285), Fragomeni S. M., D'Aviero A., Gui B., Gentileschi S. (ORCID:0000-0001-9682-4706), Corrado G., Inzani F., Morganti A. G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Tagliaferri L. (ORCID:0000-0003-2308-0982), Lancellotta, V., Macchia, Gabriella, Garganese, Giorgia, Fionda, B., Fragomeni, Simona Maria, D'Aviero, Andrea, Casa, C., Gui, Benedetta, Gentileschi, Stefano, Corrado, Giacomo, Inzani, Frediano, Rovirosa, A., Morganti, Alessio Giuseppe, Gambacorta, Maria Antonietta, Tagliaferri, Luca, Macchia G., Garganese G. (ORCID:0000-0002-4209-5285), Fragomeni S. M., D'Aviero A., Gui B., Gentileschi S. (ORCID:0000-0001-9682-4706), Corrado G., Inzani F., Morganti A. G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Tagliaferri L. (ORCID:0000-0003-2308-0982)
- Abstract
Objective: The aim of our systematic review was to assess the role of interventional radiotherapy (IRT, brachytherapy) in the management of primary and/or recurrent vulvar carcinoma. Evidence acquisition: A systematic research using PubMed, Scopus and Cochrane library was performed. ClinicalTrials.gov was searched for ongoing or recently completed trials, and PROSPERO was searched for ongoing or recently completed systematic reviews. Only full-text English-language articles related to IRT for treatment of primary or recurrent VC were identified and reviewed. Conference paper, survey, letter, editorial, book chapter and review were excluded. Time restriction (1990–2018) as concerns the years of the publication was considered. Evidence synthesis: Primary disease: the median 5-year LC was 43.5% (range 19–68%); the median 5-year DFS was 44.5% (range 44–81%); the median 5-year OS was 50.5% (range 27–85%). Recurrent disease: the median 5-year DFS was 64% (range 56–72%) and the median 5-year OS was 45% (range 33%-57%). Acute ≥ grade 2 toxicity was reported in three patients (1.6%). The severe late toxicity rates (grade 3–4) ranged from 0% to 14.3% (median 7.7%). Conclusion: IRT as part of primary treatment for primary and/or recurrent vulvar cancer is associated with promising clinical outcomes.
- Published
- 2021
42. Treatment volume, dose prescription and delivery techniques for dose-intensification in Rectal Cancer: A national survey
- Author
-
Caravatta, L., Lupattelli, M., Mantello, G., Gambacorta, Maria Antonietta, Chiloiro, Giuditta, Di Tommaso, M., Rosa, C., Gasparini, L., Morganti, Alessio Giuseppe, Picardi, V., Niespolo, R. M., Osti, M. F., Montrone, S., Simoni, N., Boso, C., Facchin, F., Deidda, M. A., Piva, C., Guida, C., Ziccarelli, L., Munoz, F., Ivaldi, G. B., Marchetti, V., Franzone, P., Spatola, C., Franco, P., Donato, V., Genovesi, D., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Chiloiro G., Morganti A. G., Caravatta, L., Lupattelli, M., Mantello, G., Gambacorta, Maria Antonietta, Chiloiro, Giuditta, Di Tommaso, M., Rosa, C., Gasparini, L., Morganti, Alessio Giuseppe, Picardi, V., Niespolo, R. M., Osti, M. F., Montrone, S., Simoni, N., Boso, C., Facchin, F., Deidda, M. A., Piva, C., Guida, C., Ziccarelli, L., Munoz, F., Ivaldi, G. B., Marchetti, V., Franzone, P., Spatola, C., Franco, P., Donato, V., Genovesi, D., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Chiloiro G., and Morganti A. G.
- Abstract
Background/Aim: The aim of the study was to investigate boost volume definition, doses, and delivery techniques for rectal cancer dose intensification. Patients and Methods: An online survey was made on 25 items (characteristics, simulation, imaging, volumes, doses, planning and treatment). Results: Thirty-eight radiation oncologists joined the study. Twenty-one delivered long-course radiotherapy with dose intensification. Boost volume was delineated on diagnostic magnetic resonance imaging (MRI) in 18 centres (85.7%), and computed tomography (CT) and/or positron emission tomography-CT in 9 (42.8%); 16 centres (76.2%) performed co-registration with CT-simulation. Boost dose was delivered on gross tumor volume in 10 centres (47.6%) and on clinical target volume in 11 (52.4%). The most common total dose was 54-55 Gy (71.4%), with moderate hypofractionation (85.7%). Intensity-modulated radiotherapy (IMRT) was used in all centres, with simultaneous integrated boost in 17 (80.8%) and image-guidance in 18 (85.7%). Conclusion: A high quality of treatment using dose escalation can be inferred by widespread multidisciplinary discussion, MRI-based treatment volume delineation, and radiation delivery relying on IMRT with accurate image-guided radiation therapy protocols.
- Published
- 2021
43. The Role of Radiotherapy in Orbital Pseudotumor: A Systematic Review of Literature
- Author
-
Fionda, B., Pagliara, M. M., Lancellotta, V., Sammarco, M. G., Casa, C., Savino, G., Deodato, F., Morganti, A. G., Gambacorta, M. A., Tagliaferri, L., Blasi, M. A., Pagliara M. M., Savino G. (ORCID:0000-0002-9993-5986), Deodato F. (ORCID:0000-0003-1276-5070), Morganti A. G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Tagliaferri L. (ORCID:0000-0003-2308-0982), Blasi M. A. (ORCID:0000-0001-7393-7644), Fionda, B., Pagliara, M. M., Lancellotta, V., Sammarco, M. G., Casa, C., Savino, G., Deodato, F., Morganti, A. G., Gambacorta, M. A., Tagliaferri, L., Blasi, M. A., Pagliara M. M., Savino G. (ORCID:0000-0002-9993-5986), Deodato F. (ORCID:0000-0003-1276-5070), Morganti A. G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Tagliaferri L. (ORCID:0000-0003-2308-0982), and Blasi M. A. (ORCID:0000-0001-7393-7644)
- Abstract
Purpose: Orbital pseudotumor (or pseudotumor orbitae) is a benign entity, also known as idiopathic orbital inflammatory syndrome (IOIS), which encompasses a wide range of non-tumoral, space occupying lesions of the orbit. In selected cases of refractory disease or presence of side effects or even comorbidities that limit systemic therapies, radiotherapy could play a role in the management because it has been demonstrated that irradiation is effective in suppressing the inflammatory process. Methods: A systematic review of the literature about the main scientific databases was launched and the time interval included all published articles present in the databases from their inception until September 2020. Results: We were able to identify 19 studies eligible for inclusion in this review from 1978 to 2018. Overall the data of 241 patients were collected and are presented in this systematic review. The response rate varied between 74% and 100% with a median recurrence rate of 10%. The median total dose was 20 Gy whereas the mean total dose was 21 Gy with a range from 4 to 36 Gy. Regarding the fractionation, 2 Gy/fraction daily was the most widely used. Conclusions: Radiotherapy seemed to achieve good response rates however, in most of the studies, inclusion criteria and outcome parameters are not uniform and therefore the results are difficult to compare. Often important parameters such as chronic pain and permanent functional deficits are not assessed in the outcome. Therefore, prospective studies, with good cohort characteristics and a clear definition of the outcome, are required.
- Published
- 2021
44. High-Dose-Rate Interstitial Brachytherapy (Interventional Radiotherapy) for Conjunctival Melanoma with Orbital Extension
- Author
-
Pagliara, M. M., Tagliaferri, L., Savino, G., Fionda, B., D'Aviero, A., Lanza, A., Lancellotta, V., Midena, G., Gambacorta, M. A., Blasi, M. A., Pagliara M. M., Tagliaferri L. (ORCID:0000-0003-2308-0982), Savino G. (ORCID:0000-0002-9993-5986), D'Aviero A., Lanza A. (ORCID:0000-0003-2187-6653), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Blasi M. A. (ORCID:0000-0001-7393-7644), Pagliara, M. M., Tagliaferri, L., Savino, G., Fionda, B., D'Aviero, A., Lanza, A., Lancellotta, V., Midena, G., Gambacorta, M. A., Blasi, M. A., Pagliara M. M., Tagliaferri L. (ORCID:0000-0003-2308-0982), Savino G. (ORCID:0000-0002-9993-5986), D'Aviero A., Lanza A. (ORCID:0000-0003-2187-6653), Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Blasi M. A. (ORCID:0000-0001-7393-7644)
- Abstract
Purpose: To evaluate local control and functional and cosmetic outcomes of postoperative high-dose-rate interventional radiotherapy (HDR-IRT) in patients affected by conjunctival melanoma with orbit invasion. Methods: A retrospective study was conducted in 2 patients affected by conjunctival melanoma infiltrating the orbit, treated with surgical excision and HDR-IRT. The treatment procedures consisted of surgical excision of the orbital infiltrating nodule followed, 1 month after surgery, by adjuvant HDR-IRT. A target dose of 34 Gy was delivered in 10 twice-a-day fractions over 5 consecutive days. Data analysis included local tumor control and metastatic rate, acute and late toxicity, functional and aesthetic results. Results: In both patients, treatment was well tolerated, and there was no orbital recurrence at a median follow-up of 37-40 months. There was an excellent functional outcome, without no significant acute or late side effects. Conclusions: HDR-IRT could be considered a promising, feasible, successful, and well-tolerated option for selected patients affected by ocular tumors with orbital invasion.
- Published
- 2021
45. The assisi think tank meeting breast large database for standardized data collection in breast cancer—attm.Blade
- Author
-
Marazzi, Fabio, Masiello, V., Masciocchi, Carlotta, Merluzzi, M., Saldi, S., Belli, Paolo, Boldrini, Luca, Capocchiano, Nikola Dino, Di Leone, Alba, Magno, Stefano, Meldolesi, Elisa, Moschella, Francesca, Mule, A., Smaniotto, Daniela, Terribile, Daniela Andreina, Tagliaferri, Luca, Franceschini, Gianluca, Gambacorta, Maria Antonietta, Masetti, Riccardo, Valentini, Vincenzo, Poortmans, P. M. P., Aristei, Cynthia, Marazzi F., Masciocchi C., Belli P. (ORCID:0000-0001-7979-2466), Boldrini L., Capocchiano N. D., Di Leone A., Magno S., Meldolesi E., Moschella F., Smaniotto D. (ORCID:0000-0002-1246-8001), Terribile D. A. (ORCID:0000-0002-3511-0010), Tagliaferri L. (ORCID:0000-0003-2308-0982), Franceschini G. (ORCID:0000-0002-2950-3395), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Masetti R. (ORCID:0000-0002-7520-9111), Valentini V. (ORCID:0000-0003-4637-6487), Aristei C., Marazzi, Fabio, Masiello, V., Masciocchi, Carlotta, Merluzzi, M., Saldi, S., Belli, Paolo, Boldrini, Luca, Capocchiano, Nikola Dino, Di Leone, Alba, Magno, Stefano, Meldolesi, Elisa, Moschella, Francesca, Mule, A., Smaniotto, Daniela, Terribile, Daniela Andreina, Tagliaferri, Luca, Franceschini, Gianluca, Gambacorta, Maria Antonietta, Masetti, Riccardo, Valentini, Vincenzo, Poortmans, P. M. P., Aristei, Cynthia, Marazzi F., Masciocchi C., Belli P. (ORCID:0000-0001-7979-2466), Boldrini L., Capocchiano N. D., Di Leone A., Magno S., Meldolesi E., Moschella F., Smaniotto D. (ORCID:0000-0002-1246-8001), Terribile D. A. (ORCID:0000-0002-3511-0010), Tagliaferri L. (ORCID:0000-0003-2308-0982), Franceschini G. (ORCID:0000-0002-2950-3395), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Masetti R. (ORCID:0000-0002-7520-9111), Valentini V. (ORCID:0000-0003-4637-6487), and Aristei C.
- Abstract
Background: During the 2016 Assisi Think Tank Meeting (ATTM) on breast cancer, the panel of experts proposed developing a validated system, based on rapid learning health care (RLHC) principles, to standardize inter-center data collection and promote personalized treatments for breast cancer. Material and Methods: The seven-step Breast LArge DatabasE (BLADE) project included data collection, analysis, application, and evaluation on a data-sharing platform. The multidisciplinary team developed a consensus-based ontology of validated variables with over 80% agreement. This English-language ontology constituted a breast cancer library with seven knowledge domains: baseline, primary systemic therapy, surgery, adjuvant systemic therapies, radiation therapy, followup, and toxicity. The library was uploaded to the BLADE domain. The safety of data encryption and preservation was tested according to General Data Protection Regulation (GDPR) guidelines on data from 15 clinical charts. The system was validated on 64 patients who had undergone post-mastectomy radiation therapy. In October 2018, the BLADE system was approved by the Ethical Committee of Fondazione Policlinico Gemelli IRCCS, Rome, Italy (Protocol No. 0043996/18). Results: From June 2016 to July 2019, the multidisciplinary team completed the work plan. An ontology of 218 validated variables was uploaded to the BLADE domain. The GDPR safety test confirmed encryption and data preservation (on 5000 random cases). All validation benchmarks were met. Conclusion: BLADE is a support system for follow-up and assessment of breast cancer care. To successfully develop and validate it as the first standardized data collection system, multidisciplinary collaboration was crucial in selecting its ontology and knowledge domains. BLADE is suitable for multi-center uploading of retrospective and prospective clinical data, as it ensures anonymity and data privacy.
- Published
- 2021
46. Functional results of exclusive interventional radiotherapy (brachytherapy) in the treatment of nasal vestibule carcinomas
- Author
-
Bussu, Francesco, Tagliaferri, Luca, De Corso, Eugenio, Passali, Giulio Cesare, Lancellotta, V., Mattiucci, Gian Carlo, Gambacorta, Maria Antonietta, Rizzo, Daniela, Di Cintio, G., Salvati, Alessandra, Paludetti, Gaetano, Valentini, Vincenzo, Galli, Jacopo, Bussu F. (ORCID:0000-0001-6261-2772), Tagliaferri L. (ORCID:0000-0003-2308-0982), De Corso E., Passali G. C. (ORCID:0000-0002-8176-0962), Mattiucci G. C. (ORCID:0000-0001-6500-0413), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Rizzo D. (ORCID:0000-0003-1809-5901), Salvati A., Paludetti G. (ORCID:0000-0003-2480-1243), Valentini V. (ORCID:0000-0003-4637-6487), Galli J. (ORCID:0000-0001-6353-6249), Bussu, Francesco, Tagliaferri, Luca, De Corso, Eugenio, Passali, Giulio Cesare, Lancellotta, V., Mattiucci, Gian Carlo, Gambacorta, Maria Antonietta, Rizzo, Daniela, Di Cintio, G., Salvati, Alessandra, Paludetti, Gaetano, Valentini, Vincenzo, Galli, Jacopo, Bussu F. (ORCID:0000-0001-6261-2772), Tagliaferri L. (ORCID:0000-0003-2308-0982), De Corso E., Passali G. C. (ORCID:0000-0002-8176-0962), Mattiucci G. C. (ORCID:0000-0001-6500-0413), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Rizzo D. (ORCID:0000-0003-1809-5901), Salvati A., Paludetti G. (ORCID:0000-0003-2480-1243), Valentini V. (ORCID:0000-0003-4637-6487), and Galli J. (ORCID:0000-0001-6353-6249)
- Abstract
Purpose: Surgery, external beam radiotherapy (EBRT), and interventional radiotherapy (IRT, BrachyTherapy BT) are the current therapeutic options for nose vestibule (NV) squamous cell carcinoma (SCC). In this article, we evaluate the nose functional parameters of patients affected by SCCs of the NV, primarily treated by interstitial IRT comparing them with healthy controls and with patients treated with intensity-modulated EBRT. Methods: Ten patients treated by using IRT (group 1), 10 healthy controls and eight patients treated by EBRT (group 2) on the region of the nose were submitted to clinical evaluation (with the NOSE scale score), rhinomanometry, olfactory testing, nasal citology, and evaluation of mucociliary clearance through saccharine test. Results: No long-term skin or cartilaginous toxicity are recorded. The olfactometry threshold discrimination identification TDI is lower in EB group. The mean NOSE scale score was significantly higher in group 2 than in group 1 and healthy controls (p < 0.05). The distribution of cytologic patterns resulted significantly different as well. Patients treated by EB have a significantly impaired mucociliary clearance, with a mean time for the transport of the stained marker, which is more than double in the patients treated by EB than in those treated with IRT (p < 0.001). Conclusions: Nasal function and cytological findings are significantly better, substantially preserved, in patients treated by IRT than in those treated by EBRT, bringing new relevant evidence for the establishment of interstitial IRT as the new standard for the treatment of the primary lesion in cT1 and cT2 -Wang staging NV SCCs.
- Published
- 2021
47. Generator breast datamart—the novel breast cancer data discovery system for research and monitoring: Preliminary results and future perspectives
- Author
-
Marazzi, Fabio, Tagliaferri, Luca, Masiello, V., Moschella, Francesca, Colloca, Giuseppe Ferdinando, Corvari, B., Sanchez, A. M., Capocchiano, Nikola Dino, Pastorino, Roberta, Iacomini, C., Lenkowicz, Jacopo, Masciocchi, Carlotta, Patarnello, S., Franceschini, Gianluca, Gambacorta, Maria Antonietta, Masetti, Riccardo, Valentini, Vincenzo, Marazzi F., Tagliaferri L. (ORCID:0000-0003-2308-0982), Moschella F., Colloca G. F., Capocchiano N. D., Pastorino R. (ORCID:0000-0001-5013-0733), Lenkowicz J., Masciocchi C., Franceschini G. (ORCID:0000-0002-2950-3395), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Masetti R. (ORCID:0000-0002-7520-9111), Valentini V. (ORCID:0000-0003-4637-6487), Marazzi, Fabio, Tagliaferri, Luca, Masiello, V., Moschella, Francesca, Colloca, Giuseppe Ferdinando, Corvari, B., Sanchez, A. M., Capocchiano, Nikola Dino, Pastorino, Roberta, Iacomini, C., Lenkowicz, Jacopo, Masciocchi, Carlotta, Patarnello, S., Franceschini, Gianluca, Gambacorta, Maria Antonietta, Masetti, Riccardo, Valentini, Vincenzo, Marazzi F., Tagliaferri L. (ORCID:0000-0003-2308-0982), Moschella F., Colloca G. F., Capocchiano N. D., Pastorino R. (ORCID:0000-0001-5013-0733), Lenkowicz J., Masciocchi C., Franceschini G. (ORCID:0000-0002-2950-3395), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Masetti R. (ORCID:0000-0002-7520-9111), and Valentini V. (ORCID:0000-0003-4637-6487)
- Abstract
Background: Artificial Intelligence (AI) is increasingly used for process management in daily life. In the medical field AI is becoming part of computerized systems to manage information and encourage the generation of evidence. Here we present the development of the application of AI to IT systems present in the hospital, for the creation of a DataMart for the management of clinical and research processes in the field of breast cancer. Materials and methods: A multidisciplinary team of radiation oncologists, epidemiologists, medical oncologists, breast surgeons, data scientists, and data management experts worked together to identify relevant data and sources located inside the hospital system. Combinations of open-source data science packages and industry solutions were used to design the target framework. To validate the DataMart directly on real-life cases, the working team defined tumoral pathology and clinical purposes of proof of concepts (PoCs). Results: Data were classified into “Not organized, not ‘ontologized’ data”, “Organized, not ‘ontologized’ data”, and “Organized and ‘ontologized’ data”. Archives of real-world data (RWD) identified were platform based on ontology, hospital data warehouse, PDF documents, and electronic reports. Data extraction was performed by direct connection with structured data or text-mining technology. Two PoCs were performed, by which waiting time interval for radiotherapy and performance index of breast unit were tested and resulted available. Conclusions: GENERATOR Breast DataMart was created for supporting breast cancer pathways of care. An AI-based process automatically extracts data from different sources and uses them for generating trend studies and clinical evidence. Further studies and more proof of concepts are needed to exploit all the potentials of this system.
- Published
- 2021
48. Could a Personalized Strategy Using Accelerated Partial Breast Irradiation be an Advantage for Elderly Patients? A Systematic Review of the Literature and Multidisciplinary Opinion
- Author
-
Tagliaferri, Luca, Lancellotta, V., Colloca, Giuseppe Ferdinando, Marazzi, Fabio, Masiello, V., Garganese, Giorgia, Kovacs, Gyorgy, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Tagliaferri L. (ORCID:0000-0003-2308-0982), Colloca G., Marazzi F., Garganese G. (ORCID:0000-0002-4209-5285), Kovacs G., Valentini V. (ORCID:0000-0003-4637-6487), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Tagliaferri, Luca, Lancellotta, V., Colloca, Giuseppe Ferdinando, Marazzi, Fabio, Masiello, V., Garganese, Giorgia, Kovacs, Gyorgy, Valentini, Vincenzo, Gambacorta, Maria Antonietta, Tagliaferri L. (ORCID:0000-0003-2308-0982), Colloca G., Marazzi F., Garganese G. (ORCID:0000-0002-4209-5285), Kovacs G., Valentini V. (ORCID:0000-0003-4637-6487), and Gambacorta M. A. (ORCID:0000-0001-5455-8737)
- Abstract
Introduction. Elderly patients are underrepresented from a majority of clinical trials and the choice of the best treatment becomes a challenge. The optimal treatment should be personalized and based on a multidisciplinary approach that includes radiation oncologists, surgeons, geriatricians, medical oncologists, social workers, and support services. The global evaluation of the patients and the creation of nomograms may facilitate the definition of long-term treatment benefits minimizing the use of unnecessary therapy. Material and Method. A systematic research using PubMed, Scopus, and Cochrane library was performed to identify full articles analyzing the efficacy of APBI in elderly patients with breast cancer. ClinicalTrials.gov was searched for ongoing or recently completed trials, and PROSPERO was searched for ongoing or recently completed systematic reviews. Results. Seven papers fulfilled the eligibility criteria. The number of evaluated patients was 405 and the median age was 77.7 years. The disease-free survival (DFS) range was 96.1%-100%, the grade 3-4 toxicity range was 0%-6.6%, the cancer-specific survival (CSS) range was 97.9%-100%, and the overall survival (OS) range was 87%-100%. All studies reported excellent/good cosmetic results in a range of 74% to 99%. Conclusion. Accelerated partial breast irradiation (APBI) results in a safe and effective substitute for the adjuvant external beam radiotherapy in selected elderly early-stage breast cancer patients. Based on the relatively low toxicity, APBI should be advised in selected patients with life expectancies larger than 5-10 years.
- Published
- 2020
49. Can brachytherapy be properly considered in the clinical practice? Trilogy project: The vision of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) Interventional Radiotherapy study group
- Author
-
Tagliaferri, Luca, Vavassori, Andrea, Lancellotta, V., de Sanctis, V., Barbera, F., Fusco, Vincenzo, Vidali, Cristiana, Fionda, B., Colloca, Giuseppe Ferdinando, Gambacorta, Maria Antonietta, Aristei, Cynthia, Corvo, R., Magrini, S. M., Tagliaferri L. (ORCID:0000-0003-2308-0982), Vavassori A., Fusco V., Vidali C., Colloca G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), Aristei C., Tagliaferri, Luca, Vavassori, Andrea, Lancellotta, V., de Sanctis, V., Barbera, F., Fusco, Vincenzo, Vidali, Cristiana, Fionda, B., Colloca, Giuseppe Ferdinando, Gambacorta, Maria Antonietta, Aristei, Cynthia, Corvo, R., Magrini, S. M., Tagliaferri L. (ORCID:0000-0003-2308-0982), Vavassori A., Fusco V., Vidali C., Colloca G., Gambacorta M. A. (ORCID:0000-0001-5455-8737), and Aristei C.
- Abstract
Purpose: Brachytherapy (BT, interventional radiotherapy – IRT) is a kind of radiation therapy, in which the radioactive source is placed nearby or even inside the cancer itself. Even though this kind of radiation therapy appears effective and valuable, BT has been facing a slow but progressive decline over the past decades in Europe, particularly in Italy. Aims of this study were to identify the practical and theoretical reasons why BT is facing a slow decline in Italy, and to define a vision of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) and a strategy about this emerged issues. Material and methods: A programmatic path divided into three steps like a trilogy was launched by AIRO Interventional Radiotherapy study group. The study group performed an initial data collection to highlight both the clinical and the educational topics and problems through specific surveys. After having analyzed the results of the surveys and shared a vision about the emerged issues, a specific strategy was adopted. Results: Four relevant domains were identified and for each ones, a strategy has been discussed and defined. This manuscript shows in detail the individual actions defined (accomplished or in progress). Conclusions: The AIRO vision implies that specific strategic interventions must be carried out in the field of national guidelines, education, research, and communication with patients and colleagues of other specialties in an interdisciplinary setting.
- Published
- 2020
50. Radiation therapy technologists’ involvement and opinion in research: A national survey in Italy
- Author
-
Piro, D., Boldrini, Luca, Cornacchione, Patrizia, Votta, C., Bianchi, M., Balducci, Mario, Gambacorta, Maria Antonietta, Valentini, Vincenzo, Pasini, Danilo, Boldrini L., Cornacchione P., Balducci M. (ORCID:0000-0003-0398-9726), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), Pasini D., Piro, D., Boldrini, Luca, Cornacchione, Patrizia, Votta, C., Bianchi, M., Balducci, Mario, Gambacorta, Maria Antonietta, Valentini, Vincenzo, Pasini, Danilo, Boldrini L., Cornacchione P., Balducci M. (ORCID:0000-0003-0398-9726), Gambacorta M. A. (ORCID:0000-0001-5455-8737), Valentini V. (ORCID:0000-0003-4637-6487), and Pasini D.
- Abstract
Introduction: This survey describes Italian RTTs’ involvement and opinions in research activities related to radiation oncology. Primary aim was to assess the degree of involvement of the national RTTs community in research and to describe how RTTs can integrate their skills collaborating with other professionals. Materials and methods: A ten-items multiple-choice questionnaire, with 2–8 possible responses, was developed by a steering committee and generated on a survey platform. Links were sent via email to Italian RTTs. The questions were divided in 3 domains: demographic data; scientific research and activity; opinions about RTTs role in scientific research. The survey started on October 1, 2018 and ended on January 31, 2019. Results: One hundred thirty-five out of 509 (26.5%) RTTs responded to the questionnaire at its expiring date; 97.73% think to be valid contributors in radiation oncology research, expressing clear interest in “data collection” tasks (52.71%); 38.64% feel unsupported by other professionals in the research team and 59.85% of the respondents are not members in any scientific society. Conclusions: The role of Italian RTTs in research is heterogeneous. Mainly RTTs in the age range from 30 to 40 years responded to the survey showing their interest in scientific research. This might be related to different informatics and educational skills as well as to personal attitudes. RTTs particular skills, like data management and technical hypothesis generation abilities, are of benefit to realize research projects. Therefore, engaging RTTs in research activities is strongly suggested.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.